[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 19413
1. Mateo J, Abarzuza R, Núñez E, Cristóbal JA: [Bilateral optic nerve infiltration in acute lymphoblastic leukemia in remission]. Arch Soc Esp Oftalmol; 2007 Mar;82(3):167-70
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral optic nerve infiltration in acute lymphoblastic leukemia in remission].
  • [Transliterated title] Infiltración bilateral del nervio óptico en un caso de leucemia aguda linfoblástica de células T en remisión.
  • CASE REPORT: An 18-year-old male affected by acute lymphoblastic leukemia (ALL) after having reached complete remission after chemotherapy developed bilateral optic nerve infiltration.
  • [MeSH-major] Leukemic Infiltration. Optic Nerve / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Fundus Oculi. Humans. Male. Papilledema / diagnosis. Prognosis. Recurrence. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357894.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Basara N, Rasche FM, Schwalenberg T, Wickenhauser C, Maier M, Ivovic J, Niederwieser D, Lindner TH: Hydronephrosis Resulting from Bilateral Ureteral Stenosis: A Late Complication of Polyoma BK Virus Cystitis? J Transplant; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here a case of acute lymphoblastic leukemia in remission presenting a late-onset bilateral hydronephrosis probably due to polyoma BK virus-induced proliferation of bladder endothelium on both ostii.
  • The diagnosis was made virologically by BK virus Polymerase Chain Reaction (PCR) detection in the absence of any other bladder disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20936157.001).
  • [ISSN] 2090-0015
  • [Journal-full-title] Journal of transplantation
  • [ISO-abbreviation] J Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2948899
  •  go-up   go-down


3. Bandyopadhyay S, Das D, Das G, Gayen S: Unilateral optic nerve infiltration as an initial site of relapse of acute lymphoblastic leukemia in remission. Oman J Ophthalmol; 2010 Sep;3(3):153-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral optic nerve infiltration as an initial site of relapse of acute lymphoblastic leukemia in remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21120055.001).
  • [ISSN] 0974-7842
  • [Journal-full-title] Oman journal of ophthalmology
  • [ISO-abbreviation] Oman J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2992166
  •  go-up   go-down


Advertisement
4. Hurtado-Sarrió M, Duch-Samper A, Taboada-Esteve J, Martínez-Dominguez JA, Senent-Peris ML, Menezo-Rozalén JL: Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib. Am J Ophthalmol; 2005 Apr;139(4):723-4
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib.
  • PURPOSE: Anterior chamber involvement is unusual in patients with acute lymphoblastic leukemia (ALL) and has never been described in the setting of Ph+ (Philadelphia chromosome-positive) ALL.
  • METHODS: A 55-year-old woman with Ph+ ALL in complete remission with imatinib and presenting unilateral anterior uveitis at initial examination was clinically evaluated.
  • RESULTS: Although there was no evidence of leukemia in the blood or bone marrow samples, aqueous fluid cytology identified Ph+ positive lymphoblastic leukemic cells.
  • [MeSH-major] Anterior Chamber / pathology. Antineoplastic Agents / therapeutic use. Eye Neoplasms / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemic Infiltration / pathology. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use
  • [MeSH-minor] Aqueous Humor / cytology. Benzamides. Female. Humans. Imatinib Mesylate. In Situ Hybridization, Fluorescence. Middle Aged. Philadelphia Chromosome. Remission Induction. Uveitis, Anterior / diagnosis


5. Mokrzycka M, Pawlik A, Kałdońska M, Millo B: Assessment of liver function in children with acute lymphoblastic leukemia in remission. Ann Acad Med Stetin; 2006;52(3):61-5; discussion 65
Hazardous Substances Data Bank. LIDOCAINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of liver function in children with acute lymphoblastic leukemia in remission.
  • PURPOSE: Acute lymphoblastic leukemia (ALL) is the most common malignant neoplasm in children.
  • MATERIAL AND METHODS: We enrolled 17 children and young adults with ALL in remission.
  • Mean remission time was 61 +/- 30 months.
  • [MeSH-major] Liver Function Tests. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Adolescent. Adult. Area Under Curve. Child. Diagnosis, Differential. Female. Half-Life. Hepatitis, Chronic / complications. Hepatitis, Chronic / diagnosis. Humans. Lidocaine / analogs & derivatives. Lidocaine / pharmacokinetics. Liver / metabolism. Male. Reference Values. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Liver Function Tests.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17385349.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 7728-40-7 / monoethylglycinexylidide; 98PI200987 / Lidocaine
  •  go-up   go-down


6. Roberson JR, Spraker HL, Shelso J, Zhou Y, Inaba H, Metzger ML, Rubnitz JE, Ribeiro RC, Sandlund JT, Jeha S, Pui CH, Howard SC: Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia. Leukemia; 2009 Feb;23(2):245-50
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia.
  • Hyperglycemia adversely affects outcome in adult patients with acute lymphoblastic leukemia (ALL), but its impact on children with this disease is unknown.
  • We evaluated the relationship between hyperglycemia during remission induction therapy and clinical outcomes among pediatric patients with ALL.
  • We reviewed the records of patients enrolled on four consecutive ALL protocols (Total Therapy protocols XIIIA, XIIIB, XIV and XV) at St Jude Children's Research Hospital from 1991 to 2007 and identified those who experienced hyperglycemia (glucose >or=200 mg per 100 ml) during remission induction.
  • Complete remission (CR) rates at the end of induction, event-free survival (EFS), overall survival (OS), cumulative incidence of relapse and occurrence of infections were compared between those who did and did not experience hyperglycemia.
  • Of 871 patients analyzed, 141 (16%) experienced hyperglycemia during remission induction.
  • Pediatric patients with or without hyperglycemia during remission induction for ALL have similar clinical outcome.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pract. 2004 Mar-Apr;10 Suppl 2:46-52 [15251640.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1677-84 [15378506.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Pediatrics. 1972 Apr;49(4):590-5 [4501679.001]
  • [Cites] Cancer Res. 1973 Jan;33(1):1-4 [4565907.001]
  • [Cites] Diabetes. 1974 Jan;23(1):9-15 [4809622.001]
  • [Cites] Diabetologia. 1978 Aug;15(2):113-6 [359390.001]
  • [Cites] Diabetes. 1980 Jul;29(7):528-31 [6991339.001]
  • [Cites] Metabolism. 1980 Dec;29(12):1262-6 [7005618.001]
  • [Cites] J Pediatr. 1981 Jul;99(1):46-50 [6454771.001]
  • [Cites] Horm Metab Res. 1984 Dec;16 Suppl 1:92-6 [6398268.001]
  • [Cites] J Trauma. 1990 Jul;30(7):830-2; discussion 832-3 [2380999.001]
  • [Cites] Indian J Cancer. 1993 Jun;30(2):72-6 [8225380.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1993 Jun;51(6):457-61 [8281494.001]
  • [Cites] FEMS Immunol Med Microbiol. 1993 Dec;7(4):315-20 [8136782.001]
  • [Cites] Arch Dis Child. 1996 Feb;74(2):101-7 [8660070.001]
  • [Cites] Horm Metab Res. 1996 Jun;28(6):267-70 [8811326.001]
  • [Cites] J Appl Physiol (1985). 1997 Nov;83(5):1566-74 [9375321.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] J Pediatr. 2005 Jan;146(1):30-4 [15644818.001]
  • [Cites] Leukemia. 2005 Apr;19(4):537-44 [15690069.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):960-3 [15700246.001]
  • [Cites] Acta Paediatr. 2006 Apr;95(4):486-93 [16720499.001]
  • [Cites] Pediatrics. 2006 Jul;118(1):173-9 [16818563.001]
  • [Cites] Pediatr Crit Care Med. 2006 Jul;7(4):351-5 [16738506.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):259-63 [17635005.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1207-12 [18266226.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1932-9 [18421047.001]
  • [Cites] Helv Paediatr Acta. 1973 Oct;28(4):365-9 [4519479.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] J Trauma. 2001 Sep;51(3):540-4 [11535907.001]
  • [Cites] J Biol Chem. 2001 Oct 12;276(41):37747-53 [11489902.001]
  • [Cites] N Engl J Med. 2001 Nov 8;345(19):1359-67 [11794168.001]
  • [Cites] Pancreas. 2002 Jan;24(1):26-33 [11741179.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):978-82 [11889147.001]
  • [Cites] Childs Nerv Syst. 2002 Apr;18(3-4):129-36 [11981619.001]
  • [Cites] Blood Rev. 2002 Dec;16(4):225-43 [12350366.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3084-91 [12915598.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2041-7 [14559958.001]
  • [Cites] J Trauma. 2003 Dec;55(6):1035-8 [14676647.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1179-85 [15022284.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] J Pediatr Surg. 2004 Jun;39(6):898-901; discussion 898-901 [15185221.001]
  • [Cites] Pediatr Crit Care Med. 2004 Jul;5(4):329-36 [15215001.001]
  • (PMID = 18923438.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / U01 GM061393-09; United States / NCI NIH HHS / CA / CA-78224; United States / NCI NIH HHS / CA / R01 CA078224-09; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / CA-60419; United States / NCI NIH HHS / CA / R37 CA036401-21; United States / NCI NIH HHS / CA / R01 CA060419-13; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; None / None / / R01 CA051001-15; United States / NCI NIH HHS / CA / CA-36401; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA-51001; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / R01 CA051001-15; United States / NCI NIH HHS / CA / P30 CA021765; None / None / / R01 CA078224-09; None / None / / P30 CA021765-30; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA036401; None / None / / R01 CA060419-13; United States / NCI NIH HHS / CA / P30 CA021765-30; United States / NIGMS NIH HHS / GM / GM-61393; United States / NCI NIH HHS / CA / U01 CA060419; United States / NCI NIH HHS / CA / CA036401-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS104861; NLM/ PMC2706830
  •  go-up   go-down


7. Murphy AJ, Wells JC, Williams JE, Fewtrell MS, Davies PS, Webb DK: Body composition in children in remission from acute lymphoblastic leukemia. Am J Clin Nutr; 2006 Jan;83(1):70-4
Hazardous Substances Data Bank. DEUTERIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body composition in children in remission from acute lymphoblastic leukemia.
  • BACKGROUND: Changes in body composition are commonly reported in pediatric survivors of acute lymphoblastic leukemia (ALL).
  • However, the effect of ALL and of its treatment on body composition in children in remission from ALL has not been fully examined with the use of a reference method.
  • OBJECTIVES: We aimed to determine the body composition and composition of fat-free mass (FFM) in children in remission from ALL.
  • DESIGN: This cross-sectional study measured height, weight, body volume, total body water, and bone mineral content in 24 children in remission from ALL and 24 age-matched, healthy control subjects.
  • Examination of the composition of FFM made it evident that children in remission from ALL had both significantly greater hydration (P = 0.001) and lower density (P = 0.0001) of FFM than did the control children.
  • CONCLUSIONS: Children in remission from ALL may develop excess body fat.
  • [MeSH-major] Adipose Tissue / metabolism. Body Composition. Body Water / metabolism. Muscle, Skeletal / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Absorptiometry, Photon. Body Mass Index. Case-Control Studies. Child. Cross-Sectional Studies. Deuterium. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Female. Humans. Male. Models, Biological. Plethysmography. Prednisolone / adverse effects. Prednisolone / therapeutic use. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400052.001).
  • [ISSN] 0002-9165
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone; AR09D82C7G / Deuterium
  •  go-up   go-down


8. Tsuji A, Sasaki M, Ishii T, Sato S, Kanki H, Suzuki S, Takeuchi S, Fukuda T: Persistent eosinophilic infiltration of the myocardium in a child in complete remission of acute lymphoblastic leukemia and eosinophilia. Potential role in late cardiac disease? Keio J Med; 2010;59(2):64-8
MedlinePlus Health Information. consumer health - Eosinophilic Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent eosinophilic infiltration of the myocardium in a child in complete remission of acute lymphoblastic leukemia and eosinophilia. Potential role in late cardiac disease?
  • This report describes the long-term (23 years) follow-up of a pediatric patient with acute lymphoblastic leukemia and eosinophilia who underwent multiple valve replacements.
  • An 8-year-old boy with this complex disease was admitted in January 1984 and treated with 6-week course of vincristine, L-asparaginase, and prednisolone, which induced complete remission.
  • The present study indicates that a subset of patients in complete remission of acute lymphoblastic leukemia and eosinophilia can show persistent myocardial eosinophilic infiltration and are at risk of late cardiac disease.
  • [MeSH-major] Cardiomyopathies / etiology. Cardiomyopathies / pathology. Eosinophilia / complications. Eosinophilia / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601842.001).
  • [ISSN] 1880-1293
  • [Journal-full-title] The Keio journal of medicine
  • [ISO-abbreviation] Keio J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Mantadakis E, Anagnostatou N, Danilatou V, Markaki EA, Spanaki AM, Briassoulis G, Kalmanti M: Fulminant hepatitis due to varicella zoster virus in a girl with acute lymphoblastic leukemia in remission: report of a case and review. J Pediatr Hematol Oncol; 2005 Oct;27(10):551-3
MedlinePlus Health Information. consumer health - Chickenpox.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fulminant hepatitis due to varicella zoster virus in a girl with acute lymphoblastic leukemia in remission: report of a case and review.
  • The authors describe a 4-year-old girl with acute lymphoblastic leukemia in remission who developed fulminant hepatic failure due to varicella-zoster virus (VZV).
  • [MeSH-major] Chickenpox / virology. Hepatitis, Viral, Human / virology. Herpesvirus 3, Human / isolation & purification. Liver Failure, Acute / virology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Fatal Outcome. Female. Humans. Immunocompromised Host. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217259.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Kim CC: Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia; 2009 Oct;23(10):1763-70
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
  • The aim of this prospective study was to investigate the feasibility of reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) in 37 adults with high-risk acute lymphoblastic leukemia (ALL) in first (n=30) or second (n=7) complete remission (CR).
  • The cumulative incidence of acute (grades II-IV) and chronic GVHD was 43.2 and 65.6%, respectively.
  • This study suggests that RIC-SCT is a potential therapeutic approach for adults with high-risk ALL in remission who are ineligible for myeloablative transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Feasibility Studies. Female. Graft Survival. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Male. Melphalan / administration & dosage. Middle Aged. Prospective Studies. Remission Induction. Risk Factors. Survival Rate. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440217.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


11. Capouya JD, Berman DM, Dumois JA: Mollaret's meningitis due to human herpesvirus 6 in an adolescent. Clin Pediatr (Phila); 2006 Nov;45(9):861-3
Hazardous Substances Data Bank. Foscarnet .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the first pediatric case of Mollaret meningitis in an adolescent female with acute lymphoblastic leukemia in remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041177.001).
  • [ISSN] 0009-9228
  • [Journal-full-title] Clinical pediatrics
  • [ISO-abbreviation] Clin Pediatr (Phila)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 364P9RVW4X / Foscarnet
  •  go-up   go-down


12. Kumar PR, Grossman Z, Scorza L, Khoury T, Nayyar R: Isolated extramedullary relapse of acute lymphoblastic leukemia in the breast of an adolescent girl: radiologic findings and discussion. Pediatr Radiol; 2010 May;40(5):773-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated extramedullary relapse of acute lymphoblastic leukemia in the breast of an adolescent girl: radiologic findings and discussion.
  • We report a case of isolated extramedullary leukemia relapse in the breast of an adolescent girl.
  • A 13-year-old girl with acute lymphoblastic leukemia in remission, post-chemotherapy and unrelated cord blood transplant, presented with a breast lump.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Neoplasm Recurrence, Local / ultrasonography. Precursor Cell Lymphoblastic Leukemia-Lymphoma / ultrasonography. Ultrasonography, Mammary / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20135115.001).
  • [ISSN] 1432-1998
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Polat M, Lenk N, Kürekçi E, Oztaş P, Artüz F, Alli N: Chronic bullous disease of childhood in a patient with acute lymphoblastic leukemia: possible induction by a drug. Am J Clin Dermatol; 2007;8(6):389-91
Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic bullous disease of childhood in a patient with acute lymphoblastic leukemia: possible induction by a drug.
  • We describe a 5-year-old boy with acute lymphoblastic leukemia in remission, in whom CBDC developed after treatment with trimethoprim/sulfamethoxazole (cotrimoxazole).
  • [MeSH-major] Anti-Infective Agents / adverse effects. Drug Eruptions / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Skin Diseases, Vesiculobullous / chemically induced. Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039023.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Immunoglobulin A; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination
  •  go-up   go-down


14. Ross A, McLean TW, Farber R, Weaver RG Jr, Chauvenet A, Givner LB, Shetty AK: Retinitis following varicella in a vaccinated child with acute lymphoblastic leukemia. Pediatr Blood Cancer; 2005 Aug;45(2):191-4
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinitis following varicella in a vaccinated child with acute lymphoblastic leukemia.
  • We report a 7-year-old patient with T-cell acute lymphoblastic leukemia in remission who presented with visual complaints 2 weeks after developing chickenpox.
  • Ophthalmologic evaluation revealed acute retinitis in the right eye.
  • Early diagnosis of VZV retinopathy and aggressive antiviral treatment is critical to prevent acute and long-term ocular sequelae.
  • [MeSH-major] Chickenpox / complications. Leukemia, T-Cell / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Retinitis / virology
  • [MeSH-minor] Acyclovir / therapeutic use. Antiviral Agents / therapeutic use. Chickenpox Vaccine / immunology. Child. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Chickenpox.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2007 Jun 15;48(7):716 [16607647.001]
  • (PMID = 15880424.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Chickenpox Vaccine; X4HES1O11F / Acyclovir
  • [Number-of-references] 33
  •  go-up   go-down


15. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Orav EJ, Colan SD: Gender differences in long-term dexrazoxane cardioprotection in doxorubicin-treated children with acute lymphoblastic leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):10005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender differences in long-term dexrazoxane cardioprotection in doxorubicin-treated children with acute lymphoblastic leukemia.
  • Adding dexrazoxane (DZR) to DOX treatment resulted in reduced myocardial injury in children with acute lymphoblastic leukemia (ALL) during Dana-Farber Cancer Institute Protocol 95-01.
  • METHODS: We centrally remeasured echocardiograms from childhood high-risk ALL survivors in their first continuous remission who were randomly assigned to treatment with DOX only (n = 66; 30 mg/m<sup>2</sup>/dose for 10 doses) or DOX plus DZR 30 minutes prior (n = 68; 300 mg/m<sup>2</sup>/dose).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962530.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Hafeez M, Shaharyar A, Zia N, Rasheed H: A phase II feasibility study of cytarabine and idarubicin combination in relapsed or refractory adult acute lymphoblastic leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e18002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II feasibility study of cytarabine and idarubicin combination in relapsed or refractory adult acute lymphoblastic leukemia.
  • It was empirically decided that the study will only be considered feasible if more then ten patients achieve a complete remission.
  • Eleven patients achieved complete remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964000.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Aigner N, Petje G, Schneider W, Meizer R, Wlk M, Kotsaris S, Knahr K, Landsiedl F: Bone marrow edema syndrome of the femoral head : Treatment with the prostacyclin analogue iloprost vs. core decompression: An MRI-controlled study. Wien Klin Wochenschr; 2005 Feb;117(4):130-135

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Knochenmarködemsyndrom des Hüftkopfes : Behandlung mit dem Prostazyklinanalogon Iloprost im Vergleich zur Hüftkopfbohrung: Eine MRT-kontrollierte Studie.
  • MRI controls showed complete remission in all hips.
  • MRI controls showed complete remission of BMES in 14 hips, residual focal bone marrow edema in four hips and a small osteonecrotic area in two hips.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28108806.001).
  • [ISSN] 1613-7671
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Keywords] NOTNLM ; Avascular necrosis / Bone marrow edema syndrome / Core decompression / Iloprost / Vasoactive drug
  •  go-up   go-down


18. Mukhopadhyay A, Gupta P, Mukhopadhyay S, Dey S, Basak J, Pandey R: Result of adolescent acute lymphoblastic leukemia protocol (MCP 841) from a developing country. J Clin Oncol; 2009 May 20;27(15_suppl):10046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Result of adolescent acute lymphoblastic leukemia protocol (MCP 841) from a developing country.
  • : 10046 Background: Acute Lymphatic Leukemia is a curable disease in the range of 80 - 90% in developed countries by aggressive protocol like BFM, St. Judes' but result is much less in adolescence age group (60-70%).
  • RESULTS: Remission induction was seen in 65 (86.7%) of the patients.
  • CONCLUSIONS: The data of acute lymphatic leukemia in adolescent is not satisfactory as compared to other pediatric patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962472.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Lonetti A, Iacobucci I, Ferrari A, Messina M, Cilloni D, Soverini S, Papayannidis C, Baccarani M, Foà R, Martinelli G: Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients. J Clin Oncol; 2009 May 20;27(15_suppl):7049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients.
  • : 7049 Since the activation-induced cytidine deaminase (AID) enzyme can target non-immunoglobulin (Ig) genes and may even act as a genome-wide mutator, we investigated AID expression in BCR-ABL1-positive ALL and in chronic myeloid leukemia (CML) at the time of progression to blast crisis.
  • On the 61 de novo adult BCR-ABL1-positive ALL patients (pts), AID mRNA and protein were detected in 36 (59%); their expression correlated with BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors at the time of remission.
  • AID expression was also found in lymphoid blast crisis CML (50%), but not in myeloid lineage or in chronic phase CML.
  • Our findings show that BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that can act as mutator outside the Ig gene loci in promoting genetic instability in leukemia cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961429.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Matsuzaki A, Suminoe A, Koga Y, Kusuhara K, Hara T, Ogata R, Sata T, Hara T: Fatal visceral varicella-zoster virus infection without skin involvement in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol; 2008 Apr-May;25(3):237-42
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal visceral varicella-zoster virus infection without skin involvement in a child with acute lymphoblastic leukemia.
  • A 5-year-old girl with acute lymphoblastic leukemia in remission suffered from fatal visceral varicella-zoster virus (VZV) infection after the oral administration of a high-dose dexamethasone.
  • [MeSH-major] Chickenpox / etiology. Herpesvirus 3, Human. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Antigens, Viral / blood. Antineoplastic Agents, Hormonal / administration & dosage. Child, Preschool. DNA, Viral / blood. Dexamethasone / administration & dosage. Disseminated Intravascular Coagulation / etiology. Fatal Outcome. Female. Humans. Liver Failure, Acute / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Chickenpox.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432508.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Antineoplastic Agents, Hormonal; 0 / DNA, Viral; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


21. Faderl S, Thomas DA, Gandhi V, Huang X, Borthakur G, O'Brien S, Ravandi F, Plunkett W, Bretz JL, Kantarjian HM: Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL). J Clin Oncol; 2009 May 20;27(15_suppl):7020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL).
  • Twenty-one pts had pre-B ALL, 5 pts pre-T/T ALL, 1 pt mature B ALL, and 3 pts biphenotypic acute leukemias.
  • Among the remainder, preceding median remission duration was 8.6 mos (1-39 mos).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961382.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Reinfjell T, Lofstad GE, Nordahl HM, Vikan A, Diseth TH: Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioning. Eur J Cancer Care (Engl); 2009 Jul;18(4):364-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioning.
  • Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioningThe objective of this study is to assess the mental health and psychosocial adjustment of children in remission from acute lymphoblastic leukaemia (ALL), and parental functioning compared to healthy controls.
  • Children in remission from ALL showed on average significantly more problems regarding mental health and psychosocial adjustment, as reported by their parents, compared with healthy controls.
  • Adequate rehabilitation and follow-up programmes should be implemented for children in remission from ALL.
  • [MeSH-major] Adaptation, Psychological. Mental Disorders / epidemiology. Parents / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology
  • [MeSH-minor] Adolescent. Adult. Anxiety / epidemiology. Child. Cross-Sectional Studies. Depression / epidemiology. Female. Health Status. Humans. Male. Middle Aged. Norway. Remission Induction. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473372.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Reinfjell T, Lofstad GE, Veenstra M, Vikan A, Diseth TH: Health-related quality of life and intellectual functioning in children in remission from acute lymphoblastic leukaemia. Acta Paediatr; 2007 Sep;96(9):1280-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life and intellectual functioning in children in remission from acute lymphoblastic leukaemia.
  • AIM: To evaluate the health-related quality of life (HRQOL) and intellectual functioning of children in remission from acute lymphoblastic leukaemia (ALL).
  • Follow-up programs that target the psychosocial health of children in remission from ALL should be implemented.
  • [MeSH-major] Cognition / physiology. Health Status. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Quality of Life / psychology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Neuropsychological Tests. Remission Induction. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Paediatr. 2007 Sep;96(9):1265-8 [17718778.001]
  • (PMID = 17590194.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


24. Ortmann J, Schiffl H, Lang SM: [Partial clinical remission of chronic IgA nephropathy with therapy of tuberculosis]. Dtsch Med Wochenschr; 2010 Jun;135(24):1228-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Partial clinical remission of chronic IgA nephropathy with therapy of tuberculosis].
  • [Transliterated title] Partielle klinische Remission einer chronischen IgA-Nephropathie unter antituberkulotischer Therapie.
  • INVESTIGATIONS: The diagnosis of the underlying etiology of the pleural effusions was difficult in spite of a thorough diagnostic work-up.
  • CONCLUSIONS: This report of a partial remission of IgA nephropathy by treatment of pleural tuberculosis supports the hypothesis that there may be a causal relationship between mycobacterial infections and IgA nephropathy.
  • [MeSH-minor] Adult. Biopsy. Drug Therapy, Combination. Humans. Kidney / pathology. Male. Pleural Effusion / diagnosis. Pleural Effusion / drug therapy. Pleural Effusion / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20533156.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


25. Ostendorf B, Scherer A, Kellner H, Backhaus M: [Project REMISSION(PLUS): clinical and radiological remission : new treatment goals in the management of rheumatoid arthritis]. Z Rheumatol; 2008 Dec;67(8):707-10, 712-5
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Project REMISSION(PLUS): clinical and radiological remission : new treatment goals in the management of rheumatoid arthritis].
  • [Transliterated title] Projekt REMISSION(PLUS): klinische und radiologische Remission : Neue Therapieziele in der Behandlung der rheumatoiden Arthritis.
  • The REMISSION(PLUS) initiative aspire to integrate modern imaging technologies as standard methods in the care and management of RA patients.
  • The main areas on which this initiative will be focusing are the conceptualization and implementation of educational programs and training seminars on sonography and MRI, the development and establishment of case report forms for standardized documentation of findings, and the systematic monitoring of patients on treatment, with the aim of producing very precise documentation of structural change processes in RA and also, if possible, to document radiological remission or even progression.
  • The REMISSION(PLUS) project also includes the setting up of specialized centers of excellence, which will network to support the implementation and access to the various imaging procedures at hospitals, rheumatology clinics and rheumatology practices nationwide.
  • [MeSH-major] Arthritis, Rheumatoid / diagnosis. Arthrography. Magnetic Resonance Imaging. Patient Care Team. Ultrasonography
  • [MeSH-minor] Documentation. Follow-Up Studies. Humans. Joints / pathology. Remission Induction. Synovial Membrane / pathology. Synovitis / diagnosis. Synovitis / therapy


26. Al-Ali HK, Wittekind C, Niederwieser D: [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab]. Dtsch Med Wochenschr; 2007 Aug;132(33):1688-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
  • [Transliterated title] Komplette Remission eines rezidivierenden Hodgkin-Lymphoms vom Mischzelligen Typ nach Rituximab-Therapie.
  • Complete remission (CR) was achieved after six cycles of doxorubicin-bleomycin-vinblastin-dacarbazine (ABVD) and cyclophosphamid-vincristine-procarbazine-prednison (COPP) regimens.
  • Histology confirmed the initial diagnosis.
  • A partial remission was induced with two further DEXA-BEAM cycles (dexamethasone, BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea], ectoposide, ara-C, melphalan).
  • A complete remission was achieved 2 months later.
  • A second treatment with rituximab yielded another complete remission which was maintained for 20 months.
  • In our patient the safety and efficacy of rituximab in relapsed CD20-positive classical HD of an MC type was demonstrated to achieve long-lasting remission.
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dacarbazine / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Humans. Lymph Nodes / pathology. Male. Melphalan / therapeutic use. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prednisone / therapeutic use. Procarbazine / therapeutic use. Remission Induction / methods. Rituximab. Treatment Outcome. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713864.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; VB0R961HZT / Prednisone; ABVD protocol; COPP protocol; Dexa-BEAM protocol
  •  go-up   go-down


27. Wolf P: [Epilepsy as a dynamic condition: facilitation and inhibition, establishment and remission]. Ugeskr Laeger; 2005 Oct 10;167(41):3865-7
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epilepsy as a dynamic condition: facilitation and inhibition, establishment and remission].
  • [Transliterated title] Epilepsi som dynamisk tilstand: fremme og haemning af anfald, etablering og remission.
  • Some of these are known, and their action can best be observed at onset, when seizure repetition is established or prevented, and at remission, when the decline of the antiepileptic drug therapeutic threshold reflects a fall in the propensity to seizures.
  • [MeSH-minor] Anticonvulsants / therapeutic use. Humans. Models, Biological. Remission, Spontaneous

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16221424.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


28. Petruskevicius I, Bukh A, Mertz H, Johnsen HE: [Complete remission after Rituximab treatment in refractory hairy cell leukemia]. Ugeskr Laeger; 2008 Jun 23;170(26-32):2350
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission after Rituximab treatment in refractory hairy cell leukemia].
  • [Transliterated title] Komplet remission efter rituximabbehandling ved refraktaer hårcelleleukaemi.
  • A 40 year-old man with hairy cell leukemia (HCL) was treated with Cladribin, but achieved only partial response (PR).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Hairy Cell / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Humans. Male. Neoplasm Recurrence, Local. Remission Induction. Rituximab

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570771.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


29. Pories W: [Type II diabetes. Permanent remission by surgery of the foregut]. Chirurg; 2009 May;80(5):416, 418-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Type II diabetes. Permanent remission by surgery of the foregut].
  • [Transliterated title] Typ-II-Diabetes : Dauerhafte Remission durch Chirurgie des Foregut.
  • Bariatric surgery offers a safe and effective treatment of type II diabetes for morbidly obese persons with complete and permanent remission as well as a clear reduction in mortality.

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440748.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Incretins
  • [Number-of-references] 22
  •  go-up   go-down


30. Haas A, Lobeck H, Hummel M, Maschmeyer G: [Prolonged remission after immunotherapy of a previously refractory peripheral T-cell non-Hodgkin lymphoma]. Dtsch Med Wochenschr; 2006 Oct 27;131(43):2386-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prolonged remission after immunotherapy of a previously refractory peripheral T-cell non-Hodgkin lymphoma].
  • [Transliterated title] Anhaltende Remission nach Immuntherapie bei zuvor refraktärem peripherem T-Non-Hodgkin-Lymphom.
  • The follow up CT-scans one year after treatment showed a stable remission.
  • CONCLUSION: In T-NHL with primary non-response it is especially difficult to induce a stable remission.
  • Despite a course which was complicated by infections and a failing response to increased chemotherapy a remission was achieved in this patient with a monotherapy of alemtuzumab for eight weeks without complications, followed by radiotherapy.
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Germany. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. L-Lactate Dehydrogenase / blood. Middle Aged. Neoplasm Staging. Prednisolone / therapeutic use. Radiotherapy, Adjuvant. Recombinant Proteins. Remission Induction. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054053.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A189DH42V / alemtuzumab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 1.1.1.27 / L-Lactate Dehydrogenase; CHOEP protocol
  •  go-up   go-down


31. Yoruk A, Erguven M, Celiker E, Aki H, Timur C, Yuksel E, Ozkan H: Spontaneous remission of acute lymphoblastic leukemia with mediastinal mass. Pediatr Hematol Oncol; 2008 Apr-May;25(3):181-6
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute lymphoblastic leukemia with mediastinal mass.
  • Spontaneous remission/regression of cancer is defined as partial or complete disappearance of malignant disease temporarily or permanently in the absence of medical treatment.
  • This event is named as spontaneous regression for solid tumors and spontaneous remission for leukemia.
  • The authors report the case of a girl aged 4 years and 3 months, who presented with mediastinal mass and leukemic findings in the bone marrow both of which reappeared after spontaneous regression and remission, respectively.
  • [MeSH-major] Mediastinal Neoplasms. Neoplasm Regression, Spontaneous. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432500.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Wolter A, Preuss U, Krischke N, Wong JW, Langosch JM, Zimmermann J: [Recovery and remission in schizophrenia. Results from a naturalistic 2-year follow-up inpatient study]. Fortschr Neurol Psychiatr; 2010 Aug;78(8):468-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recovery and remission in schizophrenia. Results from a naturalistic 2-year follow-up inpatient study].
  • [Transliterated title] Recovery und Remission bei Schizophrenie. Ergebnisse einer naturalistischen 2-Jahres-Katamnesestudie ehemals stationärer Patienten.
  • INTRODUCTION: Remission in schizophrenia is defined as a period of at least 6 months in which symptom reduction occurs.
  • Criteria of remission for each domain were assessed using the BPRS (brief psychiatric rating scale, symptomatic remission), GAF (global assessment of functioning, functional remission) and the SWN-K (subjective well-being under neuroleptics, remission of subjective well-being).
  • Approximately one-third of the individuals had remission with a stable quality of life.
  • CONCLUSION: Compared to previous studies, the rates of remission and recovery in the current sample were quite low.
  • [MeSH-minor] Adult. Age of Onset. Antipsychotic Agents / therapeutic use. Female. Follow-Up Studies. Humans. Inpatients. Longitudinal Studies. Male. Middle Aged. Prospective Studies. Psychiatric Status Rating Scales. Quality of Life. Recovery of Function. Remission, Spontaneous

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) Georg Thieme Verlag KG Stuttgart--New York.
  • (PMID = 20694939.001).
  • [ISSN] 1439-3522
  • [Journal-full-title] Fortschritte der Neurologie-Psychiatrie
  • [ISO-abbreviation] Fortschr Neurol Psychiatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


33. Foghsgaard S, Kjaergård HK: [Total remission of hemiparesis after operation in acute aortic dissection]. Ugeskr Laeger; 2008 May 5;170(19):1650-1
MedlinePlus Health Information. consumer health - Aortic Aneurysm.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Total remission of hemiparesis after operation in acute aortic dissection].
  • [Transliterated title] Fuldstaendig remission af hemiparese efter operation for akut proksimal aortadissektion.
  • Cerebral ischaemia might not preclude operation in acute aortic dissection.
  • A 37-year-old male with an acute proximal aortic dissection (type A) and coma and hemiparesis caused by involvement of the arch vessels and secondary brain malperfusion underwent emergency surgical repair with replacement of the ascending aorta in profound circulatory arrest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489876.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


34. Bannowsky A, Wefer B, Naumann M, Hamann M, Hautmann S, Jünemann KP: ["Second line" polychemotherapy in metastatic urothelial cancer of the renal pelvis. Persisting partial remission by 18 treatment cycles of gemcitabine/paclitaxel after 24 treatment cycles gemcitabine/cisplatin "stable disease"]. Urologe A; 2005 Aug;44(8):915-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ["Second line" polychemotherapy in metastatic urothelial cancer of the renal pelvis. Persisting partial remission by 18 treatment cycles of gemcitabine/paclitaxel after 24 treatment cycles gemcitabine/cisplatin "stable disease"].
  • [Transliterated title] "Second-line-Polychemotherapie" beim metastasierten Urothelkarzinom des Nierenbeckens. Andauernde partielle Remission nach 18 Kursen Gemcitabin/Paclitaxel trotz 24 Kursen Gemcitabin/Cisplatin im "stable disease".
  • We report an interesting case of a 59-year-old man suffering from urothelial cancer of the renal pelvis with pulmonary, lymphogenous, and bone metastases who had an unexpected response to "second-line" chemotherapy with only 2 treatment cycles of gemcitabine/paclitaxel (partial remission) after 24 treatment cycles of gemcitabine/cisplatin in "stable disease" with progression between the therapeutic intervals.
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Drug Administration Schedule. Drug Resistance, Neoplasm. Humans. Male. Middle Aged. Remission Induction. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / radiography. Retroperitoneal Neoplasms / secondary. Tomography, X-Ray Computed


35. Boguth K, Schenk L: [New-onset urinary incontinence in the first six month after admission into a nursing home: prevalence, incidence and remission, risk and protective factors]. Z Gerontol Geriatr; 2008 Aug;41(4):274-82
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New-onset urinary incontinence in the first six month after admission into a nursing home: prevalence, incidence and remission, risk and protective factors].
  • [Transliterated title] Neuerkrankung an Harninkontinenz in den ersten sechs Monaten nach dem Heimeintritt: Prävalenz, Inzidenz und Remission, Risiko und Schutzfaktoren.

  • Genetic Alliance. consumer health - Incontinence.
  • MedlinePlus Health Information. consumer health - Nursing Homes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677627.001).
  • [ISSN] 0948-6704
  • [Journal-full-title] Zeitschrift für Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Möller HJ, Bauer M, Fritze J, Haen E, Laux G, Müller WE, Rüther E: [Selective serotonin and noradrenaline reuptake inhibitors: a step forward in the treatment of depression?]. MMW Fortschr Med; 2005 Jan 20;147(3):43-5
MedlinePlus Health Information. consumer health - Anxiety.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Medikamentöse Behandlung von Depressionen und Angststörungen. Dem Therapieziel Remission wieder ein Schritt näher.
  • Nevertheless, only some of the patients experience a remission of their depressive symptoms.
  • [MeSH-major] Antidepressive Agents / therapeutic use. Anxiety Disorders / drug therapy. Depressive Disorder / drug therapy. Serotonin Uptake Inhibitors / therapeutic use. Symporters / antagonists & inhibitors

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15727113.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Drug Combinations; 0 / Norepinephrine Plasma Membrane Transport Proteins; 0 / SLC6A2 protein, human; 0 / Serotonin Uptake Inhibitors; 0 / Symporters
  •  go-up   go-down


37. Bertozzi S, Londero AP, Fruscalzo A, Marchesoni D, Lellé RJ: [Paget disease of the vulva: resolution after local treatment with imiquimod--report of a case and review of the literature]. Gynakol Geburtshilfliche Rundsch; 2009;49(4):326-30
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Morbus Paget der Vulva: Remission durch Lokalbehandlung mit Imiquimod--Fallbericht und Literaturübersicht.
  • Paget disease is a rare disorder of the skin of the vulva, comprising less than 1% of vulvar neoplasms.
  • Within 8 weeks, complete clinical remission was achieved.

  • Genetic Alliance. consumer health - Paget Disease.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530949.001).
  • [ISSN] 1423-0011
  • [Journal-full-title] Gynäkologisch-geburtshilfliche Rundschau
  • [ISO-abbreviation] Gynakol Geburtshilfliche Rundsch
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


38. Hindo H, Buescher ES, Frank LM, Pettit D, Dory C, Byrd R: West Nile virus infection in a teenage boy with acute lymphocytic leukemia in remission. J Pediatr Hematol Oncol; 2005 Dec;27(12):659-62
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] West Nile virus infection in a teenage boy with acute lymphocytic leukemia in remission.
  • The authors describe an adolescent with acute lymphocytic leukemia and WNV encephalitis.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. West Nile Fever / complications
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Acyclovir / therapeutic use. Adolescent. Animals. Antibodies, Viral / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiviral Agents / therapeutic use. Brain / pathology. Ceftazidime / therapeutic use. Ceftriaxone / therapeutic use. Culicidae. Diagnosis, Differential. Encephalitis, Viral / diagnosis. Fatal Outcome. Humans. Immunoglobulins, Intravenous / therapeutic use. Insect Bites and Stings / complications. Magnetic Resonance Imaging. Male. North Carolina / ethnology. Persistent Vegetative State / etiology. Prednisone / administration & dosage. Vancomycin / therapeutic use. Vincristine / administration & dosage. Virginia. West Nile virus / immunology

  • Genetic Alliance. consumer health - West nile virus.
  • MedlinePlus Health Information. consumer health - West Nile Virus.
  • Hazardous Substances Data Bank. Vancomycin .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344671.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antiviral Agents; 0 / Immunoglobulins, Intravenous; 5J49Q6B70F / Vincristine; 6Q205EH1VU / Vancomycin; 75J73V1629 / Ceftriaxone; 9M416Z9QNR / Ceftazidime; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; X4HES1O11F / Acyclovir
  •  go-up   go-down


39. Rowe JM: Optimal induction and post-remission therapy for AML in first remission. Hematology Am Soc Hematol Educ Program; 2009;:396-405
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal induction and post-remission therapy for AML in first remission.
  • Approximately 300,000 patients in the world are diagnosed annually with acute myeloid leukemia (AML).
  • The therapy of AML, unlike acute lymphoblastic leukemia (ALL), is based on maximally tolerated induction and post-remission therapy, all given within a few months from diagnosis.
  • While complete remission can be achieved in the majority of young patients, ultimate cure of the disease depends on disease eradication through the administration of post-remission therapy.
  • Harnessing the immunologic effect of graft-versus-leukemia, as in allogeneic transplantation, has further improved the outcome for many patients.
  • While 40% to 50% can achieve a complete remission, less than 10% are long-term survivors, and the cure rate of older patients has only minimally improved over the past three decades.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008225.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  • [Number-of-references] 41
  •  go-up   go-down


40. Marjanovic G, Winkler K, Schewe T, Küsters S, Hopt UT, Kulemann B, Karcz WK: [Metabolic surgery and remission of type 2 diabetes]. Dtsch Med Wochenschr; 2010 May;135(20):1020-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metabolic surgery and remission of type 2 diabetes].
  • [Transliterated title] Metabolische Chirurgie und Remission des Diabetes mellitus Typ 2.

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes, Type 2.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Weight Loss Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart * New York.
  • (PMID = 20461659.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


41. Steinherz PG, Meyers PA, Steinherz LJ, Jeha S: Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia. J Pediatr Hematol Oncol; 2007 Sep;29(9):656-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia.
  • Clofarabine is a new nucleoside analog that has demonstrated clinical benefit in phase I-II studies, and is currently being studied in children and adults with leukemias and has been approved for the treatment of children with relapsed or refractory acute lymphocytic leukemia.
  • We report the experience of three adolescents, two with acute lymphocytic leukemia in 3rd relapse and one with relapsed/refractory acute myeloid leukemia, who achieved complete remission with clofarabine.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Arabinonucleosides / therapeutic use. Leukemia, Myeloid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Female. Humans. Male. Recurrence. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805046.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  •  go-up   go-down


42. Isaacs KL: How rapidly should remission be achieved? Dig Dis; 2010;28(3):548-55
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How rapidly should remission be achieved?
  • The major goal of therapy in inflammatory bowel disease is to induce remission.
  • Remission has multiple definitions - clinical remission, where the patient's symptoms have remitted, and endoscopic remission, in which there has been complete mucosal healing.
  • Mucosal healing is a harder endpoint of remission but may be more difficult to achieve.
  • Ideally we would like to see remission as quickly as possible to improve patient quality of life.
  • The time to remission varies between different therapeutic approaches.
  • Steroids tend to have a rapid clinical effect with remission seen in some patients as early as two weeks.
  • In early anti-TNF trials, a single dose of infliximab lead to 27% remission at two weeks compared to 4% of placebo patients.
  • Adalimumab and certolizumab have similar reports of early induction of remission.
  • Mesalamine in Crohn's disease has inconsistent and delayed remission rates, whereas in ulcerative colitis, response and remission rates are more consistent in the three-week time frame.
  • Azathioprine and 6-mercaptopurine have delayed onset of action but may induce remission as early as six weeks if dosing is optimized.
  • In this presentation induction of clinical remission and mucosal healing in Crohn's disease and ulcerative colitis will be discussed.
  • The impact of early remission on disease course will also be reviewed.
  • [MeSH-minor] Humans. Intestinal Mucosa / pathology. Remission Induction. Wound Healing

  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20926885.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


43. Shammas RM, Ranganath VK, Paulus HE: Remission in rheumatoid arthritis. Curr Rheumatol Rep; 2010 Oct;12(5):355-62
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in rheumatoid arthritis.
  • With advancing therapeutic options, achieving a state of remission has become the treatment goal in rheumatoid arthritis.
  • Agreeing on what constitutes remission and what measures should be used to assess disease activity has remained a challenge.
  • Multiple remission criteria have been devised and modified, all with different strengths and limitations.
  • A consensus definition of remission will need to be achieved if we are to be able to evaluate outcomes of clinical trials and establish treatment targets for practice.
  • Remission defined as the complete absence of disease currently may not be a realistic therapeutic goal.
  • [MeSH-minor] Humans. Remission Induction. Terminology as Topic

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 2004 Jan;31(1):1-4 [14705208.001]
  • [Cites] Rheumatology (Oxford). 2009 Sep;48(9):1092-7 [19561156.001]
  • [Cites] Arthritis Rheum. 1981 Oct;24(10):1308-15 [7306232.001]
  • [Cites] Br J Rheumatol. 1996 Nov;35(11):1101-5 [8948296.001]
  • [Cites] Nat Rev Rheumatol. 2010 Feb;6(2):68-70 [20125170.001]
  • [Cites] Autoimmun Rev. 2010 Jan;9(3):161-4 [19602456.001]
  • [Cites] Scand J Rheumatol. 2010;39(1):12-8 [20132065.001]
  • [Cites] J Rheumatol. 2010 Feb;37(2):285-90 [20080905.001]
  • [Cites] Rheumatology (Oxford). 2010 Apr;49(4):683-90 [20047979.001]
  • [Cites] Arthritis Res Ther. 2010;12(1):R3 [20055986.001]
  • [Cites] J Rheumatol. 2010 Jul;37(7):1444-53 [20516031.001]
  • [Cites] J Rheumatol. 2001 Feb;28(2):355-9 [11246676.001]
  • [Cites] Rheum Dis Clin North Am. 1997 Feb;23(1):195-212 [9031383.001]
  • [Cites] Ann Rheum Dis. 2005 Oct;64(10):1410-3 [15941836.001]
  • [Cites] Arthritis Rheum. 2005 Nov;52(11):3554-62 [16255044.001]
  • [Cites] Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S100-8 [16273793.001]
  • [Cites] Semin Arthritis Rheum. 2005 Dec;35(3):185-96 [16325659.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-1-6 [17083755.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-14-21 [17083757.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-22-8 [17083758.001]
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3761-73 [17133543.001]
  • [Cites] Z Rheumatol. 2006 May;65(3):209-12, 214-6 [16670812.001]
  • [Cites] Ann Rheum Dis. 2007 Mar;66(3):358-63 [16935911.001]
  • [Cites] Arthritis Res Ther. 2007;9(4):R72 [17662115.001]
  • [Cites] South Med J. 2008 Mar;101(3):240-5 [18364651.001]
  • [Cites] Arthritis Rheum. 2008 Aug;58(8):2241-7 [18668546.001]
  • [Cites] Arthritis Rheum. 2008 Sep;58(9):2642-51 [18759292.001]
  • [Cites] Arthritis Rheum. 2008 Sep 15;59(9):1241-8 [18759316.001]
  • [Cites] N Engl J Med. 1948 Jan 29;238(5):142-8 [18921122.001]
  • [Cites] Arthritis Rheum. 2008 Oct;58(10):2958-67 [18821687.001]
  • [Cites] Rheumatol Int. 2008 Dec;29(2):131-9 [18807254.001]
  • [Cites] BMC Musculoskelet Disord. 2009;10:41 [19389230.001]
  • [Cites] Ann Rheum Dis. 2009 Jun;68(6):914-21 [18662933.001]
  • [Cites] Arthritis Rheum. 2009 May 15;61(5):704-10 [19405006.001]
  • [Cites] J Rheumatol. 2009 May;36(5):930-3 [19332634.001]
  • [Cites] Arthritis Rheum. 2009 May;60(5):1242-9 [19404938.001]
  • [Cites] J Rheumatol. 2009 Jul;36(7):1532-5 [19487265.001]
  • [Cites] Arthritis Rheum. 2009 Aug;60(8):2262-71 [19644846.001]
  • [Cites] Arthritis Rheum. 2004 Jan;50(1):36-42 [14730597.001]
  • (PMID = 20697983.001).
  • [ISSN] 1534-6307
  • [Journal-full-title] Current rheumatology reports
  • [ISO-abbreviation] Curr Rheumatol Rep
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K23 AR057818
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2927687
  •  go-up   go-down


44. Horikoshi Y, Kobayashi R, Endo M, Watanabe A, Kikuta A, Koike K, Hanada R, Hosoya R, Ohara A, Ikuta K, Goto H, Asami K, Sugita K, Horibe K, Tsurusawa M, Hori T, Hara J, Nishimura S, Nagatoshi Y, Mugishima H, Ohta S, Adachi S, Tsukimoto I: [Effectiveness of remission induction with high-dose cytarabine for relapsed or refractory pediatric acute leukemia]. Rinsho Ketsueki; 2010 Feb;51(2):104-13
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effectiveness of remission induction with high-dose cytarabine for relapsed or refractory pediatric acute leukemia].
  • We conducted a multicenter postmarketing study to investigate the efficacy and safety of reinduction therapy with a high-dose cytarabine-containing regimen for pediatric patients with relapsed or refractory acute leukemia.
  • Seven of 13 patients (53.8%) with ALL achieved complete or partial remission, and only 1 of 6 patients (16.7%) with AML achieved partial remission.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Invasive Pulmonary Aspergillosis / etiology. Invasive Pulmonary Aspergillosis / prevention & control. Leukemia, Myeloid, Acute / drug therapy. Male. Pulse Therapy, Drug. Recurrence. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379101.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


45. Steinherz PG, Shukla N, Kobos R, Steinherz L: Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatr Blood Cancer; 2010 May;54(5):687-93
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
  • BACKGROUND: We determined the maximum tolerated dose (MTD) of clofarabine when administered with topotecan, vinorelbine, thiotepa, and dexamethasone (TVTC) for children with relapsed or refractory acute leukemia, and observed the efficacy and toxicities of this therapy.
  • PROCEDURE: Twelve patients with acute lymphoblastic or myeloblastic leukemia were given a 14-day remission induction therapy.
  • Patients who achieved a remission proceeded to a stem cell transplant (HSCT).
  • One patient died on day 45 with marrow hypoplasia without evidence of leukemia.
  • CONCLUSION: TVTC has significant anti-leukemic activity in both acute lymphoblastic and myeloblastic leukemia.
  • This is the recommended dose for the phase II study in patients with refractory or relapsed leukemia, a population which has limited therapeutic options.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy
  • [MeSH-minor] Adenine Nucleotides / administration & dosage. Adenine Nucleotides / adverse effects. Adolescent. Adult. Arabinonucleosides / administration & dosage. Arabinonucleosides / adverse effects. Child. Child, Preschool. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Hematopoietic Stem Cell Transplantation. Humans. Infant. Male. Maximum Tolerated Dose. Recurrence. Remission Induction. Thiotepa / administration & dosage. Thiotepa / adverse effects. Topotecan / administration & dosage. Topotecan / adverse effects. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205253.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 5V9KLZ54CY / Vinblastine; 762RDY0Y2H / clofarabine; 7M7YKX2N15 / Topotecan; 905Z5W3GKH / Thiotepa; Q6C979R91Y / vinorelbine
  •  go-up   go-down


46. van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, Bernardo M, Arango C, Fleischhacker W, Lachaux B, Kane JM: Standardized remission criteria in schizophrenia. Acta Psychiatr Scand; 2006 Feb;113(2):91-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standardized remission criteria in schizophrenia.
  • OBJECTIVE: Recent work has focussed on schizophrenia as a 'deficit' state but little attention has been paid to defining illness plasticity in terms of symptomatic remission.
  • METHOD: A qualitative review of a recently proposed concept of remission [N.C.
  • RESULTS: The proposed definition of remission is conceptually viable, and can be easily implemented in clinical trials and clinical practice.
  • The availability of validated outcome measures based on remission will enhance the conduct and reporting of clinical investigations, and could facilitate the design and interpretation of new studies on cognition and functional outcomes.
  • While useful as a concept, it is important to consider that remission is distinct from recovery.
  • CONCLUSION: The introduction of standardized remission criteria may offer significant opportunities for clinical practice, health services research and clinical trials.
  • [MeSH-minor] Chronic Disease. Clinical Trials as Topic / standards. Follow-Up Studies. Humans. Remission Induction / methods

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Psychiatr Scand. 2007 Feb;115(2):163-4; author reply 164 [17244184.001]
  • [CommentIn] Acta Psychiatr Scand. 2006 Feb;113(2):81 [16423157.001]
  • (PMID = 16423159.001).
  • [ISSN] 0001-690X
  • [Journal-full-title] Acta psychiatrica Scandinavica
  • [ISO-abbreviation] Acta Psychiatr Scand
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 13
  •  go-up   go-down


47. Lakshmi C, Srinivas CR: Granuloma annulare - remission with PUVASOL. Indian J Dermatol; 2010;55(1):97-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granuloma annulare - remission with PUVASOL.
  • A 64-year-old man with generalized papular granuloma annulare of four years duration with frequent relapses and remissions presented with persistent lesions while on 15 mg prednisolone and achieved complete remission with PUVASOL therapy using solarium.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Dermatol. 1988 Jan;13(1):26-7 [3208437.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2003 Jan-Feb;69(1):10-1 [17642813.001]
  • [Cites] Br J Dermatol. 2001 May;144(5):996-9 [11359387.001]
  • [Cites] Arch Dermatol. 1990 Mar;126(3):356-8 [2138005.001]
  • (PMID = 20418988.001).
  • [ISSN] 1998-3611
  • [Journal-full-title] Indian journal of dermatology
  • [ISO-abbreviation] Indian J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2856384
  • [Keywords] NOTNLM ; Bath-PUVA / granuloma annulare / solarium
  •  go-up   go-down


48. Friedrich C, Schrum J, Chott A, Janka-Schaub G, Kabisch H: Ongoing remission after intensive ALL-type chemotherapy in pediatric intestinal T-cell lymphoma. Pediatr Blood Cancer; 2010 Apr;54(4):610-2
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ongoing remission after intensive ALL-type chemotherapy in pediatric intestinal T-cell lymphoma.
  • Our patient remains in first remission 30 months after finishing the acute lymphoblastic leukemia protocol COALL-07-03 high risk standard.
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Child. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Methylprednisolone / administration & dosage. Neoplasm Staging. Receptors, Antigen, T-Cell, gamma-delta / genetics. Remission Induction. Thioguanine / administration & dosage. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20049930.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; FTK8U1GZNX / Thioguanine; X4W7ZR7023 / Methylprednisolone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


49. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G: Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood; 2009 Feb 26;113(9):1892-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.
  • Pretreatment aberrant DNA methylation patterns are stable at time of relapse in acute lymphocytic leukemia (ALL).
  • We hypothesized that the detection of residual methylation alterations at the time of morphologic remission may predict for worse prognosis.
  • We developed a real-time bisulfite polymerase chain reaction assay and analyzed the methylation levels of p73, p15, and p57(KIP2) at the time of initial remission in 199 patients with Philadelphia chromosome-negative and MLL(-) ALL.
  • In 123 (65%) patients, matched pretreatment samples were also studied and compared with remission ones: in 82 of those with initial aberrant methylation of at least one gene, 59 (72%) had no detectable methylation at remission and 23 (28%) had detectable residual methylation.
  • By multivariate analysis, the presence of residual p73 methylation was associated with a significant shorter duration of first complete remission (hazard ratio=2.68, P= .003) and overall survival (hazard ratio=2.69, P= .002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D25-30 [18073190.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):163-205 [11253606.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):11-9 [11262868.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1897-903 [12060634.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2217-24 [12114423.001]
  • [Cites] Blood. 2003 May 15;101(10):4131-6 [12586619.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1845-50 [12970785.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2492-8 [15198948.001]
  • [Cites] Hematol Oncol Clin North Am. 1993 Feb;7(1):139-60 [8449856.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3932-9 [15851765.001]
  • [Cites] Leuk Res. 2005 Aug;29(8):881-5 [15978938.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1370-7 [17283175.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1381-96, x-xi [11147229.001]
  • (PMID = 19109226.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA105771; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA100067; United States / NCI NIH HHS / CA / R21 CA100067; United States / NCI NIH HHS / CA / CA105771
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  • [Other-IDs] NLM/ PMC2651008
  •  go-up   go-down


50. van Os J, Kahn R: [Remission criteria in schizophrenia]. Tijdschr Psychiatr; 2007;49(1):21-6
MedlinePlus Health Information. consumer health - Schizophrenia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Remission criteria in schizophrenia].
  • [Transliterated title] Remissiecriteria voor de diagnose schizofrenie.
  • AIM: An internationally accepted standard definition of symptomatic remission.
  • METHOD: Two international panels of experts have wrestled with the problem of whether or how symptomatic remission in persons diagnosed with schizophrenia can be defined.
  • Acceptance of the remission concept can raise expectations about treatment outcome to a higher level than is possible when a patient is merely defined as being 'stable', can improve the quality of treatment documentation and facilitate the dialogue concerning treatment expectations.
  • The availability of validated outcome measures based on remission should enhance the reporting and the comparability of clinical research and should facilitate the design and interpretation of new research into the relation between symptomatic remission and functional outcomes.
  • CONCLUSION: The introduction of standard remission criteria can create many opportunities for clinical practice, clinical research and cumulative records of results; at the same time it can facilitate a dialogue with patients and help to clarify the diagnosis of schizophrenia.
  • [MeSH-major] Outcome Assessment (Health Care) / standards. Remission Induction. Schizophrenia. Schizophrenic Psychology
  • [MeSH-minor] Diagnosis, Differential. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225202.001).
  • [ISSN] 0303-7339
  • [Journal-full-title] Tijdschrift voor psychiatrie
  • [ISO-abbreviation] Tijdschr Psychiatr
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 15
  •  go-up   go-down


51. Potenza L, Luppi M, Riva G, Marasca R, Martinelli S, Torelli G: Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission. Haematologica; 2005 Sep;90(9):1275-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
  • Seven Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients in first complete remission received maintenance therapy with imatinib alone.
  • (iii) only the wide and rapid increment of BCR-ABL values was predictive of leukemia relapse.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Remission Induction


52. Marisavljevic D, Markovic O, Zivkovic R: An unusual case of smoldering AML with prolonged indolent clinical course and spontaneous remission in the terminal phase. Med Oncol; 2009 Dec;26(4):476-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of smoldering AML with prolonged indolent clinical course and spontaneous remission in the terminal phase.
  • An unusual case of acute myeloblastic leukemia (AML) with indolent clinical course and spontaneous remission in the terminal phase is described.
  • Five years from diagnosis patient exhibited spontaneous remission of the disease, accompanied with disappearance of del(6q) clone.
  • Additional curiosity in this case is the fact that patient's older brother died of acute lymphoblastic leukemia at the age of 71 years.
  • Possible mechanisms of spontaneous remission of AML and genetic predisposition for human leukemia are discussed with a review of the literature.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Regression, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130323.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. de Vlam K, Lories RJ: Remission in psoriatic arthritis. Curr Rheumatol Rep; 2008 Aug;10(4):297-302
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in psoriatic arthritis.
  • PsA has a low likelihood of clinical remission and cure.
  • Remission may now be an attainable outcome in the treatment paradigm.
  • At this time, specific tools to define PsA remission are not available.
  • New assessments to define remission must be developed and incorporated into clinical trials and longitudinal registries.
  • [MeSH-minor] Female. Humans. Male. Remission Induction


54. Yoshimi A, Taoka K, Nakasone H, Iijima K, Kida M, Iki S, Urabe A, Usuki K: [Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia]. Rinsho Ketsueki; 2006 Dec;47(12):1533-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia].
  • We report a case of an adult patient with acute lymphoblastic leukemia (ALL) who developed SSST during the remission induction therapy.
  • He received a 1-AdVP regimen as remission induction therapy and intrathecal administration of methotrexate and cytarabine.
  • Lymphoid malignancy (ALL in particular), the use of L-Asp, CNS involvement, and intrathecal chemotherapy might be risk factors for the occurrence SSST.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Asparaginase / administration & dosage. Asparaginase / adverse effects. Central Nervous System Neoplasms / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Sagittal Sinus Thrombosis / etiology
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Cytarabine / adverse effects. Doxorubicin / administration & dosage. Facial Paralysis / etiology. Humans. Injections, Spinal. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Remission Induction. Risk Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Thrombosis.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233472.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


55. Yoon JH, Park JA, Kim EK, Kang HJ, Shin HY, Ahn HS: Improvement of induction remission rate by modifying the dose of idarubicin for relapsed childhood acute lymphoblastic leukemia. J Korean Med Sci; 2009 Apr;24(2):281-8
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of induction remission rate by modifying the dose of idarubicin for relapsed childhood acute lymphoblastic leukemia.
  • Relapse is the major cause of treatment failure in acute lymphoblastic leukemia (ALL), yet there is no established treatment for relapsed ALL.
  • To improve the induction remission rate, we modified the dose of idarubicin in the original Children's Cancer Group (CCG)-1884 protocol, and retrospectively compared the results.
  • Complete remission (CR) rate in all patients after induction chemotherapy was 57%.
  • Remission failure due to treatment-related mortality (TRM) was 44% and 5.2% in the idarubicin 12.5 mg/m(2)/week and 10 mg/m(2)/week groups, respectively (p=0.011).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Idarubicin / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Recurrence. Remission Induction. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Med Pediatr Oncol. 2000 May;34(5):313-8 [10797352.001]
  • [Cites] Pediatr Blood Cancer. 2004 Oct;43(5):571-9 [15382275.001]
  • [Cites] Cancer. 1980 Jun 15;45(12):3090-4 [6930318.001]
  • [Cites] Tumori. 1980 Oct 31;66(5):549-64 [6936969.001]
  • [Cites] N Engl J Med. 1981 Oct 8;305(15):846-51 [7024804.001]
  • [Cites] N Engl J Med. 1986 Jul 31;315(5):273-8 [3523250.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2990-5 [3471321.001]
  • [Cites] Blood. 1987 Jul;70(1):324-6 [3297205.001]
  • [Cites] Blood. 1988 Oct;72(4):1286-92 [3167209.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6525-8 [2208112.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1666-74 [2015395.001]
  • [Cites] Blood. 1992 Jan 15;79(2):313-9 [1730080.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):124-9 [1734217.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1103-11 [1607916.001]
  • [Cites] Blood. 1991 Nov 15;78(10):2780-4 [1824271.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):352-8 [7844596.001]
  • [Cites] Med Pediatr Oncol. 1996 Dec;27(6):505-14 [8888809.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):534-40 [9324340.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):671-7 [9401083.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] Br J Haematol. 1998 Jul;102(2):423-38 [9695956.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Feb;28(2):64-8 [16462575.001]
  • [Cites] Curr Opin Hematol. 2006 Jul;13(4):260-5 [16755223.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):581-7 [12209751.001]
  • (PMID = 19399271.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC2672129
  • [Keywords] NOTNLM ; Idarubicin / Precursor Cell Lymphoblastic Leukemia-Lymphoma / Recurrence / Remission Induction
  •  go-up   go-down


56. Masuko M, Furukawa T, Yersser O, Narita M, Toba K, Koike T, Aizawa Y: Persistence of various chromosomal aberrations in recipient cells during complete remission after bone marrow transplantation followed by graft rejection. Leuk Res; 2005 Sep;29(9):1083-7
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of various chromosomal aberrations in recipient cells during complete remission after bone marrow transplantation followed by graft rejection.
  • A 16-year-old boy in a second remission of acute lymphoblastic leukemia (ALL) had undergone transplantation of bone marrow from an unrelated donor.
  • Although the donor marrow was rejected, hematopoiesis by the recipient himself recovered and he has remained in complete remission for more than 8 years after stem cell transplantation (SCT).
  • Although complete remission was maintained, various chromosomal aberrations were detected in marrow cells, and in peripheral blood cells under phytohemagglutinin stimulation over 8 years.
  • This persistence of various chromosomal aberrations and a stable clone without evolution to myelodysplastic syndrome or leukemia support the multi step theory of leukemogenesis.
  • [MeSH-major] Bone Marrow Transplantation. Chromosome Aberrations. Graft Rejection. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Remission Induction

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038736.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Laverdière C, Michon B, Schorin M, Schwartz CL, O'Brien JE, Cohen HJ, Sallan SE: Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood; 2010 Feb 18;115(7):1351-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.
  • Over the past several decades, L-asparaginase, an important component of therapy for acute lymphoblastic leukemia (ALL), has typically been administered intramuscularly rather than intravenously in North America because of concerns regarding anaphylaxis.
  • Between 2005 and 2007, 197 patients (age, 1-17 years) were enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 05-01 and received a single dose of intravenous PEG-asparaginase (2500 IU/m(2)) over 1 hour during remission induction.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Asparaginase / administration & dosage. Polyethylene Glycols / administration & dosage. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Feasibility Studies. Humans. Infant. Infusions, Intravenous. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1525-32 [10735901.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2247-56 [11187916.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Feb;49(2):149-54 [11862429.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1986-94 [11877270.001]
  • [Cites] Pediatr Blood Cancer. 2010 Feb;54(2):199-205 [19672973.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5601-7 [6352020.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1780-6 [8355045.001]
  • [Cites] Blood. 2007 Feb 1;109(3):896-904 [17003366.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2744-50 [17132721.001]
  • [Cites] Pediatr Blood Cancer. 2009 Aug;53(2):162-7 [19405141.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4554-8 [6895481.001]
  • (PMID = 20007809.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00400946
  • [Grant] United States / NCI NIH HHS / CA / P01 CA068484; United States / NCI NIH HHS / CA / 5 P01CA068484
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 30IQX730WE / Polyethylene Glycols; 7D96IR0PPM / pegaspargase; EC 3.5.1.1 / Asparaginase
  • [Other-IDs] NLM/ PMC2826760
  •  go-up   go-down


58. Orsi C, Bartolozzi B, Messori A, Bosi A: Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation. Bone Marrow Transplant; 2007 Oct;40(7):643-9
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation.
  • Allogeneic transplantation in patients with acute lymphoblastic leukaemia in first remission (ALL-CR1) has been studied in several clinical trials.
  • [MeSH-major] Bone Marrow Transplantation / physiology. Disease-Free Survival. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660839.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Marks DI, Pérez WS, He W, Zhang MJ, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ: Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood; 2008 Jul 15;112(2):426-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission.
  • We report the retrospective outcomes of unrelated donor (URD) transplants in 169 patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) who received transplants between 1995 and 2004.
  • A total of 50% had a white blood cell count (WBC) more than 30 x 10(9)/L, 18% extramedullary disease, 42% achieved CR more than 8 weeks from diagnosis, 25% had adverse cytogenetics, and 19% had T-cell leukemia.
  • At 54-month median follow-up, incidences of acute grade 2-IV, III to IV, and chronic graft-versus-host disease were 50%, 25%, and 43%, respectively.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2005 Mar;35(6):549-56 [15756282.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58 [18541193.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1572-7 [11238093.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Dec;14(4):793-805 [11924922.001]
  • [Cites] Haematologica. 2003 May;88(5):555-60 [12745275.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1619-28 [7632972.001]
  • [Cites] Bone Marrow Transplant. 1998 Jan;21(2):153-8 [9489632.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):931-6 [9508175.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2236-46 [10498594.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3028-37 [15256423.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):683-9 [16113673.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(2):155-63 [16284608.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2657-63 [16703597.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5695-702 [17116940.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Blood. 2007 Jul 1;110(1):409-17 [17374741.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [CommentIn] Blood. 2008 Jul 15;112(2):212 [18606879.001]
  • [CommentIn] Blood. 2008 Jul 15;112(2):447-8; author reply 448-9 [18606892.001]
  • (PMID = 18398065.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2442751
  •  go-up   go-down


60. van Os J, Drukker M, à Campo J, Meijer J, Bak M, Delespaul P: Validation of remission criteria for schizophrenia. Am J Psychiatry; 2006 Nov;163(11):2000-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of remission criteria for schizophrenia.
  • OBJECTIVE: Remission criteria for schizophrenia have been proposed, consisting of a time criterion and a symptomatic remission criterion.
  • With longitudinal data of a representative patient group (N=317; median follow-up: 1,132 days), validity of the symptomatic remission criterion was investigated.
  • METHOD: In a group of 145 patients meeting the symptomatic remission criterion at baseline and a group of 172 patients not meeting it at baseline, change over time in remission status was examined in relation to change in various functional outcomes.
  • RESULTS: In both groups, change over time with the symptomatic remission criterion was associated with substantial changes in unmet needs, Global Assessment of Functioning scale scores, satisfaction with services and, to a lesser extent, quality of life.
  • Changing the symptomatic remission criterion to include depression and suicidality did not affect the results.
  • CONCLUSIONS: The proposed symptomatic remission criterion has clinical validity and represents the right balance between parsimony and inclusiveness.
  • [MeSH-minor] Depressive Disorder / psychology. Follow-Up Studies. Humans. Longitudinal Studies. Patient Satisfaction. Quality of Life. Reproducibility of Results. Sensitivity and Specificity. Suicide / psychology. Time Factors

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17074953.001).
  • [ISSN] 0002-953X
  • [Journal-full-title] The American journal of psychiatry
  • [ISO-abbreviation] Am J Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Wang H, Li D, Li JT, Wang XL, Hao LC: [Side effects of L-asparaginase during therapies for remission induction and maintenance in children with acute lymphocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun;17(3):739-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Side effects of L-asparaginase during therapies for remission induction and maintenance in children with acute lymphocytic leukemia].
  • This study was purposed to investigate the possible side effects of L-asparaginase (L-ASP) in the treatment of patients with acute lymphoblastic leukemia (ALL) and to explore the correlation of these side effects at different therapeutic stages by means of retrospective analysis, so as to reduce the incidence of side effects and improve the safety of chemotherapy and the long-term survival of patients.
  • The probability and severity of side effects related to use of L-ASP in 38 cases of ALL during remission induction therapy (VDLDex regimen) and 40 cases of ALL during maintenance intensive therapy (VMLDex regimen) were compared.
  • The results showed that allergic response, diabetes and drug-induced liver disease happened more frequently during maintenance therapy than during remission induction therapy, while defibrination, abnormal hemagglutinin, acute pancreatitis, hypoproteinemia, gastrointestinal reaction and infectious shock were observed more during remission induction therapy than those at maintenance therapy.
  • In conclusion, the L-ASP showed some side effects especially for the patients during the remission induction therapy which should be paid enough attention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549398.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


62. Kavanaugh A, Fransen J: Defining remission in psoriatic arthritis. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-83-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining remission in psoriatic arthritis.
  • In other conditions, such as rheumatoid arthritis, recent discussions have centered on how best to define "remission."
  • For patients with PsA, the heterogeneity among disease manifestations as well as the need to validate outcome measures make definition of remission challenging.
  • In this paper we present a number of key principles and considerations critical to laying the groundwork for defining remission in PsA.
  • [MeSH-minor] Finger Joint / immunology. Humans. Inflammation / drug therapy. Practice Guidelines as Topic. Reference Values. Remission Induction. Toe Joint / immunology


63. Afify Z, Hunt L, Green A, Guttridge M, Cornish J, Oakhill A: Factors affecting the outcome of stem cell transplantation from unrelated donors for childhood acute lymphoblastic leukemia in third remission. Bone Marrow Transplant; 2005 Jun;35(11):1041-7
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting the outcome of stem cell transplantation from unrelated donors for childhood acute lymphoblastic leukemia in third remission.
  • Between July 1990 and March 2002, 35 consecutive children with ALL in third complete remission (CR3) underwent stem cell transplantation (SCT) from unrelated donors (UD).
  • Short first complete remission (CR1) <2.5 years was associated with lower EFS (P=0.001), higher TRM (P=0.019) and higher relapse rate (P=0.023).
  • Short second complete remission (CR2) <2.5 years was associated with lower EFS (P=0.003) and higher TRM (0.009).
  • [MeSH-major] Bone Marrow Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm. Antigens, CD34 / biosynthesis. Disease-Free Survival. Female. Graft vs Host Disease / prevention & control. Humans. Immunophenotyping. Male. Postoperative Complications. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Risk Factors. T-Lymphocytes / cytology. Time Factors. Treatment Outcome


64. Zochling J, Braun J: Remission in ankylosing spondylitis. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-88-92
MedlinePlus Health Information. consumer health - Ankylosing Spondylitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in ankylosing spondylitis.
  • Remission is a major goal of medical therapy in chronic disease.
  • The concept of disease remission in AS has not received much attention in the current literature.
  • There exists one set of partial remission criteria formally developed by the ASsessments in Ankylosing Spondylitis (ASAS) working group on the basis of clinical trials with nonsteroidal anti-inflammatory drugs for use in clinical trials.
  • As more effective therapies become available for AS, disease remission is increasingly regarded as an appropriate therapeutic goal that may then be translated into modification of progressive structural damage.
  • There is a need to further define and evaluate current proposals concerning remission in AS.
  • [MeSH-minor] Antirheumatic Agents / therapeutic use. Clinical Trials as Topic. Humans. Practice Guidelines as Topic. Remission Induction

  • Genetic Alliance. consumer health - Ankylosing Spondylitis.
  • Genetic Alliance. consumer health - Spondylitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083769.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  • [Number-of-references] 40
  •  go-up   go-down


65. Sokka T, Mäkinen H: Remission makes its way to rheumatology. Arthritis Res Ther; 2010;12(4):129
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission makes its way to rheumatology.
  • Remission was a rare event, even in the most advanced rheumatology clinics, until recent times.
  • However, in the early 1990s, it was chosen as the treatment goal and the primary outcome measure for the Finnish Rheumatoid Arthritis Combination Therapy (FIN-RACo) trial, which can be considered the beginning of remission's way to rheumatology.
  • In addition to remission in patients with rheumatoid arthritis, remission in patients with psoriatic arthritis is now being studied, although remission criteria for psoriatic arthritis have yet to be defined.
  • [MeSH-minor] Humans. Remission Induction

  • MedlinePlus Health Information. consumer health - Psoriatic Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 1981 Oct;24(10):1308-15 [7306232.001]
  • [Cites] Arthritis Res Ther. 2010;12(3):R94 [20482783.001]
  • [Cites] Lancet. 1999 May 8;353(9164):1568-73 [10334255.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1009-19 [15818706.001]
  • [Cites] J Rheumatol. 2005 May;32(5):796-800 [15868611.001]
  • [Cites] Arthritis Rheum. 2005 Nov;52(11):3381-90 [16258899.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-22-8 [17083758.001]
  • [Cites] J Rheumatol. 2007 Feb;34(2):316-21 [17183623.001]
  • [Cites] Rheumatology (Oxford). 2007 Jun;46(6):1020-3 [17405761.001]
  • [Cites] Ann Rheum Dis. 2008 Jun;67(6):815-22 [17878209.001]
  • [Cites] Curr Rheumatol Rep. 2008 Aug;10(4):297-302 [18662510.001]
  • [Cites] Arthritis Rheum. 2008 Sep;58(9):2642-51 [18759292.001]
  • [Cites] Ann Rheum Dis. 2008 Dec;67(12):1710-5 [18218667.001]
  • [Cites] Ann Rheum Dis. 2010 Apr;69(4):631-7 [20215140.001]
  • [Cites] Arthritis Rheum. 1984 Aug;27(8):864-72 [6431998.001]
  • (PMID = 20642867.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  • [Other-IDs] NLM/ PMC2945015
  •  go-up   go-down


66. Advani AS, Jin T, Ramsingh G, Tiu R, Saber W, Theil K, Sobecks R, Sekeres M, Copelan E, Sungren S, Tripp B, Kalaycio M: Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia. Leuk Lymphoma; 2008 Aug;49(8):1560-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia.
  • Cox proportional hazards analysis was used to identify univariate and multivariate correlates of complete remission, overall survival and progression-free survival.
  • On univariate analysis, significant prognostic factors included: age at diagnosis (per 10-year increase), poor risk cytogenetics, time to white blood count recovery, and time from induction chemotherapy (IC) to post-remission therapy (PRT).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Cytogenetic Analysis. Humans. Middle Aged. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18766970.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Hafiz MG, Mannan MA: Nutritional status at initial presentation in childhood acute lymphoblastic leukemia and its effect on induction of remission. Mymensingh Med J; 2008 Jul;17(2 Suppl):S46-51
MedlinePlus Health Information. consumer health - Malnutrition.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutritional status at initial presentation in childhood acute lymphoblastic leukemia and its effect on induction of remission.
  • This prospective study was aimed to evaluate the nutritional status at initial presentation in childhood acute lymphoblastic leukemia (ALL) and to ascertain the effects of nutrition on induction of remission.
  • Then, protocol based induction of remission was started.
  • Optimum nutritional support can play a vital role in the outcome of induction of remission in childhood ALL.


68. Mato AR, Luger SM: Autologous stem cell transplant in ALL: who should we be transplanting in first remission? Bone Marrow Transplant; 2006 Jun;37(11):989-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplant in ALL: who should we be transplanting in first remission?
  • Long-term disease-free survival (DFS) has been reported after autologous stem cell transplantation for acute lymphoblastic leukemia.
  • Phase II studies have evaluated its role in first and subsequent complete remission (CR) with DFS rates of up to 50%.
  • Although variability in the available studies makes it difficult to draw a definite conclusion, and many issues remain unresolved, available data suggests that there may be a group of patients for whom ASCT in first remission is a reasonable and perhaps superior treatment choice.
  • Factors such as risk features at diagnosis, and minimal residual disease following induction therapy greatly affect outcome following ASCT.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Bone Marrow Purging. Clinical Trials as Topic. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Neoplasm, Residual. Patient Selection. Recurrence. Remission Induction. Transplantation, Autologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633362.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 41
  •  go-up   go-down


69. Stow P, Key L, Chen X, Pan Q, Neale GA, Coustan-Smith E, Mullighan CG, Zhou Y, Pui CH, Campana D: Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood; 2010 Jun 10;115(23):4657-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.
  • Minimal residual disease (MRD) at the end of remission-induction therapy predicts relapse in acute lymphoblastic leukemia (ALL).
  • MRD measurements of 0.001% to less than 0.01% were not significantly related to presenting characteristics but were associated with a poorer leukemia cell clearance on day 19 of remission induction therapy.
  • Thus, low levels of MRD (0.001%-< 0.01%) at the end of remission induction therapy have prognostic significance in childhood ALL, suggesting that patients with this finding should be monitored closely for adverse events.


70. Mitsuishi T, Iida K, Kawana S: Papulonecrotic tuberculid with spontaneous remission. J Dermatol; 2006 Feb;33(2):112-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papulonecrotic tuberculid with spontaneous remission.
  • We describe a 62-year-old Japanese woman who had skin lesions involving her extremities, chest and back that showed spontaneous remission.
  • [MeSH-minor] Biopsy, Needle. Female. Humans. Immunohistochemistry. Japan. Middle Aged. Rare Diseases. Remission, Spontaneous. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556278.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


71. Ram R, Gafter-Gvili A, Vidal L, Paul M, Ben-Bassat I, Shpilberg O, Raanani P: Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis. Cancer; 2010 Jul 15;116(14):3447-57
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis.
  • BACKGROUND: The optimal postremission therapy in adults with acute lymphoblastic leukemia (ALL) is still a matter of debate.
  • The objective of this study was to compare the various potential therapeutic options for patients who achieved first complete remission.
  • CONCLUSIONS: Overall, alloSCT was superior to ASCT or chemotherapy for patients with ALL in first complete remission.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Randomized Controlled Trials as Topic. Recurrence. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • (PMID = 20564092.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


72. Ranganath VK, Khanna D, Paulus HE: ACR remission criteria and response criteria. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-14-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACR remission criteria and response criteria.
  • Many clinical studies now are geared toward evaluating the concept of eradicating inflammation as a method to seek the elusive goal of sustained remission in RA.
  • One of the first descriptions of remission in 'RA' was by Short et al in 1948, when he documented the natural progression of the disease.
  • Since that time, various criteria have been developed to define RA remission utilizing clinical, radiographic, and laboratory measures.
  • The most stringent of criteria is the American College of Rheumatology Remission Criteria, developed in 1980, which consists of clinical symptoms and signs of inflammation including fatigue, joint pain, morning stiffness, joint tenderness, joint swelling, and erythrocyte sedimentation rate (ESR).
  • Several reports have compared ACR remission criteria to Disease Activity Score (DAS) values to identify equivalent DAS remission values, and these have been extrapolated to modified versions of the DAS, the Simple Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI).
  • The ACR remission criteria and the response measures were not designed for use as the target or goal for the clinical management of individual RA patients in routine clinical practice.
  • Nevertheless, rheumatologists yearn for the eradication of inflammation in all RA patients, and attaining remission may be achievable in the future.
  • [MeSH-minor] Clinical Trials as Topic. Female. Humans. Male. Practice Guidelines as Topic / standards. Remission Induction. Research Design. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083757.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  • [Number-of-references] 52
  •  go-up   go-down


73. Pincus T, Kavanaugh A, Aletaha D, Smolen J: Complexities in defining remission in rheumatic diseases. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-1-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complexities in defining remission in rheumatic diseases.
  • The rheumatology community has devoted increasing attention to the subject of remission over the past 2 decades, on the basis of greater appreciation of the long-term severity of inflammatory rheumatic diseases and availability of new therapies and approaches to improve outcomes.
  • Nonetheless, description of remission in rheumatic diseases is complex, compared to many nonrheumatic diseases.
  • Recognition of remission requires a set of measures or an index rather than a single "gold standard."
  • Spontaneous remission is not infrequent in people with early inflammatory arthritis, including some who may meet criteria for rheumatoid arthritis (RA) over less than a few months, and may be confused with a drug-induced remission.
  • Remission may be transient in many patients over short periods, and the length of time required to maintain remission status varies in different reports.
  • Maintenance of a state of remission in autoimmune diseases that result from dysregulatory processes, rather than invasion of foreign cells or toxins, generally requires ongoing therapy indefinitely.
  • Patients who have organ damage or functional disability may be described as "in remission," although they are free of disease activity only, but not necessarily free of disease consequences.
  • A status of "low disease activity" or "near remission" with 70% to 90% of the features of an ideal remission may be adequate for many people with rheumatic diseases to avoid risks that may be required to reach 100% remission status.
  • Thus, the subject of remission remains under active discussion in the rheumatology community.
  • [MeSH-minor] Humans. Remission Induction. Secondary Prevention

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083755.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  • [Number-of-references] 76
  •  go-up   go-down


74. Ma MH, Scott IC, Kingsley GH, Scott DL: Remission in early rheumatoid arthritis. J Rheumatol; 2010 Jul;37(7):1444-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in early rheumatoid arthritis.
  • OBJECTIVE: We systematically reviewed remission as an outcome measure in observational studies and randomized controlled trials (RCT) in early rheumatoid arthritis (RA).
  • Our objectives were to identify its frequency using different criteria, to determine the influence of different treatment strategies on remission, and to review the effects of remission on radiological outcomes.
  • METHODS: Pubmed, Medline and Embase were searched using the following terms: Early Rheumatoid Arthritis or Early RA combined with Remission, Treatment, anti-Tumor Necrosis Factor (TNF) or Disease-modifying Antirheumatic Drugs (DMARD).
  • RESULTS: Seventeen observational studies (4762 patients) reported remission in 27% of patients, 17% by ACR criteria and 33% by DAS criteria.
  • Observational studies showed continuing radiological progression despite remission.
  • RCT showed less radiological progression in remission when treated with combination therapy compared to monotherapies.
  • CONCLUSION: Remission is a realistic treatment goal in early RA.
  • Radiological progression occurred in remission but is reduced by combination therapies.
  • ACR and DAS remission criteria are not directly comparable and standardization is needed.
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Databases, Factual. Humans. Meta-Analysis as Topic. Randomized Controlled Trials as Topic. Remission Induction. Treatment Outcome. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Rheumatol. 2010 Jul;37(7):1371-3 [20595289.001]
  • (PMID = 20516031.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


75. Narasimhan M, Kannaday MH: Treating depression and achieving remission. Asian J Psychiatr; 2010 Dec;3(4):163-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating depression and achieving remission.
  • Despite all the advances in understanding the biological underpinnings of depression and the extensive armamentarium of antidepressants remission is a difficult goal to achieve.
  • There are several hurdles to achieving remission including accuracy of diagnosis, partial response, suboptimization of the medication, and failure to capture residual symptoms.
  • There is an urgent need to implement strategies to achieve remission including destigmatizing mental illness, educating patients, their families, optimizing treatments, exploring novel interventions and addressing residual symptoms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier B.V.
  • (PMID = 23050881.001).
  • [ISSN] 1876-2026
  • [Journal-full-title] Asian journal of psychiatry
  • [ISO-abbreviation] Asian J Psychiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


76. Dhédin N, Dombret H, Thomas X, Lhéritier V, Boiron JM, Rigal-Huguet F, Vey N, Kuentz M, Reman O, Witz F, Delannoy A, Kovacsovics T, Bradstock K, Charrin C, Boucheix C, Gabert J, Blaise D, Fière D, Vernant JP: Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia; 2006 Feb;20(2):336-44
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials.
  • To evaluate the results of autologous stem cell transplantation (ASCT) in a large population of adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR), we performed an individual data-based overview of the last three trials from the LALA group.
  • [MeSH-major] Peripheral Blood Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Recurrence. Remission Induction. Risk Factors. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357838.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


77. Gonvers JJ, Juillerat P, Mottet C, Felley C, Burnand B, Vader JP, Michetti P, Froehlich F: Maintenance of remission in Crohn's disease. Digestion; 2005;71(1):41-8
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maintenance of remission in Crohn's disease.
  • When remission of Crohn's disease is achieved, the next goal is to maintain long-term remission.
  • Aminosalicylates may be recommended for maintenance remission, even though the results are less consistent than those observed in ulcerative colitis.
  • Corticosteroids are not effective in maintaining remission and should not be used for this indication.
  • Azathioprine and 6-mercaptopurine are effective in maintaining remission.
  • Methotrexate has also been found to be effective in maintaining remission in Crohn's disease in patients who have responded acutely to methotrexate.
  • Mycophenolate mofetil could be considered a therapy in patients who are either allergic to azathioprine or in whom azathioprine failed to induce remission.
  • In patients refractory to other therapies, infliximab may be effective in maintaining remission.
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Drug Therapy, Combination. Gastrointestinal Agents / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15711049.001).
  • [ISSN] 0012-2823
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gastrointestinal Agents; 0 / Immunosuppressive Agents
  • [Number-of-references] 63
  •  go-up   go-down


78. Schimmele CM, Wu Z, Penning MJ: Gender and remission of mental illness. Can J Public Health; 2009 Sep-Oct;100(5):353-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender and remission of mental illness.
  • The objective of this study was to determine whether gender also influences the timing of remission from illness.
  • The regression analysis undertaken considered remission in terms of all ICD-9 mental disorders (codes 290-314).
  • This analysis compares males and females on average length of treatment for mental illness and examines whether any gender differences in remission are generalized or disorder specific.
  • The target population represented all individuals with an ICD-9 diagnosis of mental illness who were treated through the Medical Services Plan in British Columbia.
  • RESULTS: There was a non-significant bivariate relation between gender and the timing of remission from mental illness.
  • However, the multivariate findings demonstrated that a significant gender effect on remission emerges after controls were introduced for demographic and socio-economic characteristics.
  • In particular, the timing of remission was somewhat longer for females.
  • CONCLUSIONS: The emergence of a significant effect after considering demographic and socio-economic characteristics suggests that a social disadvantage within the male sample (more single males) was suppressing a small negative effect of female gender on the timing of remission.
  • In other words, a social disadvantage among males concealed an unexplained female disadvantage in remission.

  • Genetic Alliance. consumer health - Mental Illness.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • MedlinePlus Health Information. consumer health - Mental Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19994736.001).
  • [ISSN] 0008-4263
  • [Journal-full-title] Canadian journal of public health = Revue canadienne de sante publique
  • [ISO-abbreviation] Can J Public Health
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R24 HD042828; None / None / / R24 HD042828-10; United States / NICHD NIH HHS / HD / R24 HD042828-10; Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


79. Fouillard L, Labopin M, Gratwohl A, Gluckman E, Frassoni F, Beelen DW, Willemze R, Montserrat E, Blaise D, Atienza AI, Sierra J, Santos M, Gorin NC, Rocha V, Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation: Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission. Haematologica; 2008 Jun;93(6):834-41
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
  • BACKGROUND: The possibility of performing syngeneic hematopoietic stem cell transplantation is rare and there are concerns about the absence of a graft-versus-leukemia effect following such a strategy.
  • We report the outcomes of a large series of adult patients who underwent syngeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia or acute lymphoblastic leukemia.
  • DESIGN AND METHODS: The outcomes of all syngeneic transplants for acute myeloblastic or lymphoblastic leukemia reported to the European Group for Blood and Marrow Transplantation registry were analyzed; a study of prognostic factors was performed for those transplanted in first complete remission.
  • RESULTS: One hundred and sixty-two patients, 109 with acute myeloblastic leukemia and 53 with acute lymphoblastic leukemia, were identified; 116 were in first complete remission.
  • Nineteen patients developed acute graft-versus-host disease and only three patients developed chronic graft-versus-host disease.
  • At 5 years the non-relapse mortality was 8 +/- 5%, the relapse incidence 49 +/- 8% and the leukemia-free survival 43 +/- 3%.
  • The corresponding figures for patients in first complete remission were 7 +/- 2%, 40 +/- 4% and 53 +/- 5% at 5 years.
  • Analysis of patients in first complete remission showed that the number of courses of chemotherapy required to induce first complete remission was the main risk factor: the leukemia-free survival at 5 years was 66 +/- 6% when first complete remission was reached after one induction course of chemotherapy and was only 20 +/- 9% when first complete remission was reached after at least two induction courses of chemotherapy (p = 0.0001); the relapse incidence was 30 +/- 6% and 54 +/- 10%, respectively (p = 0.007).
  • CONCLUSIONS: Outcomes were better for patients transplanted in first complete remission than in second complete remission or a more advanced phase of the disease.
  • When a syngeneic donor is available for patients with high risk acute leukemia, allotransplantation should be performed as soon as the first complete remission has been achieved, ideally with one course of chemotherapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Diseases in Twins. Female. Graft vs Host Disease. Humans. Male. Middle Aged. Recurrence. Remission Induction. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Jun;93(6):801-5 [18515876.001]
  • (PMID = 18469352.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


80. Ravelli A, Martini A: Remission in juvenile idiopathic arthritis. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S105-10
MedlinePlus Health Information. consumer health - Juvenile Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in juvenile idiopathic arthritis.
  • Until recently, no uniform and widely accepted criteria for defining remission in juvenile idiopathic arthritis (JIA) were available.
  • In recent years, a set of preliminary criteria for clinical remission in JIA was developed through an international collaborative effort.
  • These criteria enable the classification of patients in the states of inactive disease, clinical remission with medication, and clinical remission without medication.
  • A few studies have applied the new remission criteria in series of patients with JIA, with results that concur with those of previous surveys in showing that only a few patients with JIA have a chance of remaining in long-term remission status without medications.
  • [MeSH-minor] Clinical Trials as Topic. Humans. Inflammation / drug therapy. Inflammation / physiopathology. Remission Induction. Survivors

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Arthritis, Juvenile.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083772.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 31
  •  go-up   go-down


81. Agrawal S, Unterberg M, Koschmieder S, zur Stadt U, Brunnberg U, Verbeek W, Büchner T, Berdel WE, Serve H, Müller-Tidow C: DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res; 2007 Feb 1;67(3):1370-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.
  • Epigenetic changes play an important role in leukemia pathogenesis.
  • DNA methylation is among the most common alterations in leukemia.
  • The potential role of DNA methylation as a biomarker in leukemia is unknown.
  • We analyzed the potential of aberrant DNA promoter methylation as a biomarker for MRD in acute leukemias.
  • Methylation analyses were done in >370 DNA specimens from 180 acute leukemia patients and controls.
  • Methylation of ERalpha and/or p15(INK4B) occurred frequently and specifically in acute leukemia but not in healthy controls or in nonmalignant hematologic diseases.
  • Aberrant DNA methylation was detectable in >20% of leukemia patients during clinical remission.
  • In pediatric acute lymphoblastic leukemia, methylation levels during clinical remission correlated closely with T-cell receptor/immunoglobulin MRD levels (r = +0.7, P < 0.01) and were associated with subsequent relapse.
  • In acute myelogenous leukemia patients in clinical remission, increased methylation levels were associated with a high relapse risk and significantly reduced relapse-free survival (P = 0.003).
  • Many patients with acute leukemia in clinical remission harbor increased levels of aberrant DNA methylation.
  • Analysis of methylation MRD might be used as a novel biomarker for leukemia patients' relapse risk.
  • [MeSH-major] DNA Methylation. Genes, Tumor Suppressor. Leukemia, Myeloid / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Cyclin-Dependent Kinase Inhibitor p15 / metabolism. Estrogen Receptor alpha / genetics. Estrogen Receptor alpha / metabolism. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Neoplasm, Residual. Polymerase Chain Reaction. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Risk Factors

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283175.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Estrogen Receptor alpha
  •  go-up   go-down


82. Gonvers JJ, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Michetti P, Froehlich F: Maintenance of medically induced remission of Crohn's disease. Digestion; 2007;76(2):116-29
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maintenance of medically induced remission of Crohn's disease.
  • The natural history of Crohn's disease is characterized by recurring flares alternating with periods of inactive disease and remission.
  • This implies that most patients need to take medication for a large period of their life, mostly for maintenance of remission and, intermittently, additional therapy during a flare.
  • Low-dose systemic corticosteroids are not effective in maintaining remission and should not be used for this indication.
  • There is a trend towards a prolonged time to relapse in patients in remission who are treated with budenoside, a corticosteroid with high topical anti-inflammatory activity and low systemic activity.
  • Azathioprine and 6-mercaptopurine are effective in maintaining remission.
  • Methotrexate has also been found to be effective in maintaining remission in Crohn's disease in patients who have responded acutely to methotrexate.
  • In patients refractory to other therapies, infliximab may be effective in maintaining remission.
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antibodies, Monoclonal / therapeutic use. Drug Therapy, Combination. Gastrointestinal Agents / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18239403.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; 0 / Immunosuppressive Agents
  • [Number-of-references] 103
  •  go-up   go-down


83. Leucht S, Lasser R: The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry; 2006 Sep;39(5):161-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The concepts of remission and recovery in schizophrenia.
  • OBJECTIVE: To examine the past and current research into the concepts of remission and recovery in schizophrenia.
  • DATA SOURCES: An electronic literature search of studies published between January 1990-April 2005 examining the concepts of remission and recovery in schizophrenia and the treatment of schizophrenia with antipsychotic agents was performed using Medline and EMBASE.
  • Primary research parameters were 'schizophrenia', 'remission', 'recovery', 'meta-analysis', 'antipsychotics', 'atypicals', 'conventional', 'cognition', 'function' and 'quality of life'.
  • DATA SYNTHESIS: A number of different definitions of remission and recovery have been previously used, which has made comparison of study results problematic.
  • Recently, the first operational definition of remission, based on Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria (DSM-IV) for schizophrenia, was developed.
  • Recovery, which encompasses both symptom remission and more functional aspects of patient's well being, such as cognition, social functionality and quality of life, is still to be satisfactorily defined.
  • CONCLUSIONS: Until the definition for 'recovery' is further elucidated, factors such as symptom control and remission, and functional aspects of recovery such as improvements in cognition and social functioning, which are quantifiable, should be used as measures of treatment outcome and markers of recovery.

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944406.001).
  • [ISSN] 0176-3679
  • [Journal-full-title] Pharmacopsychiatry
  • [ISO-abbreviation] Pharmacopsychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  • [Number-of-references] 77
  •  go-up   go-down


84. Sirohi B, Powles R, Treleaven J, Kulkarni S, Saso R, Potter M, Ethell M, Morgan G, Singhal S, Mehta J: The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients. Bone Marrow Transplant; 2008 Jul;42(2):105-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients.
  • Age 30 years, >4 weeks to attain remission, and karyotypes t(4;11) and t(9;22) were associated with adverse outcome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


85. Badell I, Muñoz A, Ortega JJ, Martínez A, Madero L, Bureo E, Verdeguer A, Fernandez-Delgado R, Cubells J, Soledad-Maldonado M, Olivé T, Sastre A, Baro J, Díaz MA, Spanish Working Party for BMT in Children (GETMON): Long-term outcome of allogeneic or autologous haemopoietic cell transplantation for acute lymphoblastic leukaemia in second remission in children. GETMON experience 1983-1998. Bone Marrow Transplant; 2005 May;35(9):895-901
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of allogeneic or autologous haemopoietic cell transplantation for acute lymphoblastic leukaemia in second remission in children. GETMON experience 1983-1998.
  • We present a retrospective study of long-term outcome and predictive factors of survival and relapse in 219 paediatric patients with acute lymphoblastic leukaemia (ALL) in second remission.
  • Significantly better EFS was observed in allo-HCT patients under 10 years of age and in auto-HCT patients with leukocytes at diagnosis below 25 x 109/l and late relapse.
  • Factors predictive for relapse were medullary and early relapse, auto-HCT and WBC >25 x 109/l at diagnosis.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15778727.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Nielsen L, Toft N, Eckersall PD, Mellor DJ, Morris JS: Serum C-reactive protein concentration as an indicator of remission status in dogs with multicentric lymphoma. J Vet Intern Med; 2007 Nov-Dec;21(6):1231-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum C-reactive protein concentration as an indicator of remission status in dogs with multicentric lymphoma.
  • BACKGROUND: The acute-phase protein C-reactive protein (CRP) is used as a diagnostic and prognostic marker in humans with various neoplasias, including non-Hodgkin's lymphoma.
  • OBJECTIVE: To evaluate if CRP could be used to detect different remission states in dogs with lymphoma.
  • Blood samples were collected at the time of diagnosis, before each chemotherapy session, and at follow-up visits, resulting in 287 serum samples.
  • After achieving complete remission 90% (18/20) of the dogs had CRP concentrations within the reference range, and the difference in values before and after treatment was statistically significant (P < .001).
  • CRP concentrations of dogs in complete remission (median, 1.91; range, 0.2-103) were significantly different (P = .031) from those of dogs with partial remission (median, 2.48; range, 0-89), stable disease (median, 1.77; range, 1.03-42.65), or progressive disease (median, 8.7; range, 0-82.5).
  • CONCLUSIONS: CRP is useful in determining complete remission status after treatment with cytotoxic drugs.
  • However, the individual variation between dogs means CRP concentration is not sufficiently different in other remission states to permit its use in monitoring progression of the disease.
  • Greater reliability in determining remission status might be achieved by combining CRP concentration with other serum markers.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18196731.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


87. Chan GS, Chim S, Fan YS, Chan KW: Focal segmental glomerulosclerosis after membranous glomerulonephritis in remission: temporal diversity of glomerulopathy after bone marrow transplantation. Hum Pathol; 2006 Dec;37(12):1607-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal segmental glomerulosclerosis after membranous glomerulonephritis in remission: temporal diversity of glomerulopathy after bone marrow transplantation.
  • We describe a 13-year-old boy who had matched unrelated donor allogeneic BMT for relapsed acute lymphoblastic leukemia, complicated by chronic graft-versus-host disease.
  • Immunosuppressive therapy achieved good clinical remission, and treatment was stopped after 15 months.


88. Voskuyl AE, Dijkmans BA: Remission and radiographic progression in rheumatoid arthritis. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-37-40
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission and radiographic progression in rheumatoid arthritis.
  • Complete remission, defined as the presence of clinical as well as radiographic remission, is the ultimate goal of treatment of rheumatoid arthritis (RA).
  • Whether radiographic progression is entirely dependent on the presence of joint inflammation is a matter of debate; some evidence suggests that radiologic progression may continue in patients who appear clinically to be in remission.
  • Better diagnosis of joint damage will assist in our quest to attain and document full remission in RA.
  • Until these techniques are validated and assessed for predictive value, we would advocate that radiographic progression be added to existing criteria for clinical remission, in order to define remission in RA more comprehensively.
  • [MeSH-minor] Disease Progression. Humans. Predictive Value of Tests. Remission Induction. Severity of Illness Index

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083761.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 28
  •  go-up   go-down


89. Kotov AS, Rudakova IG, Kotov SV: [Non-terminal remission in epileptic patients]. Zh Nevrol Psikhiatr Im S S Korsakova; 2008;108(11):16-20
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-terminal remission in epileptic patients].
  • Non-terminal remission (temporal stop of seizures with the following relapse) has been diagnosed in 18,3% of cases.
  • An aim of the study was to investigate clinical characteristics and prognosis in patients with such type of remission.
  • As a result, patients were diagnosed with idiopathic generalized epilepsy (18 cases), epilepsy with rare, usually secondary generalized, seizures (37 cases), drug-induced remission (46 cases) and long-term spontaneous remission usually associated with late childhood and adolescence (18 cases).
  • In conclusion, patients with non-terminal remission represent a heterogeneous group with different character of epileptic syndromes, forms of disease and prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19008795.001).
  • [ISSN] 1997-7298
  • [Journal-full-title] Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
  • [ISO-abbreviation] Zh Nevrol Psikhiatr Im S S Korsakova
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


90. Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández-Rivas JM, Moreno MJ, del Potro E, Torm M, Rivas C, Besalduch J, Sanz MA, Ortega JJ, PETHEMA Group, Spain: Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica; 2005 Oct;90(10):1346-56
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
  • BACKGROUND AND OBJECTIVES: The optimal post-remission therapy for adults with high-risk acute lymphoblastic leukemia (ALL) is not well established.
  • This multicenter randomized trial by the Spanish PETHEMA Group was addressed to compare three options of post-remission therapy in adults with high-risk ALL: chemotherapy, allogeneic stem cell transplantation (SCT) and autologous SCT.
  • Patients in complete remission with an HLA-identical family donor were assigned to allogeneic SCT (n=84) and the remaining were randomized to autologous SCT (n=50) or to delayed intensification followed by maintenance chemotherapy up to 2 years in complete remission (n=48).
  • RESULTS: Overall, 183 patients achieved complete remission (82%).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Risk Factors. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Oct;90(10):1299 [16219555.001]
  • (PMID = 16219571.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


91. Olmsted MP, Kaplan AS, Rockert W: Defining remission and relapse in bulimia nervosa. Int J Eat Disord; 2005 Jul;38(1):1-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining remission and relapse in bulimia nervosa.
  • OBJECTIVE: The goals of the current study were to compare the relapse rates obtained when definitions of both remission and relapse were systematically varied and to propose some consensus definitions related to relapse in bulimia nervosa (BN).
  • RESULTS: Relapse rates at 19 months ranged from 21% to 55% depending on the definitions of remission and relapse applied.
  • DISCUSSION: Relapse rates are strongly influenced by definitions of remission and relapse.
  • We propose that partial remission, defined as a maximum of two symptom episodes per month for 2 months, should constitute eligibility for relapse and relapse should be defined as meeting full diagnostic criteria for 3 months.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 by Wiley Periodicals, Inc
  • [CommentIn] Int J Eat Disord. 2005 Jul;38(1):7-8 [15971234.001]
  • (PMID = 15971233.001).
  • [ISSN] 0276-3478
  • [Journal-full-title] The International journal of eating disorders
  • [ISO-abbreviation] Int J Eat Disord
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


92. Mizuta S, Kohno A, Morishita Y, Atsuta Y, Sao H, Miyamura K, Sakamaki H, Ueda R, Morishima Y: Long-term follow-up of 14 patients with philadelphia chromosome-positive acute lymphoblastic leukemia following autologous bone marrow transplantation in first complete remission. Int J Hematol; 2007 Feb;85(2):140-5
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of 14 patients with philadelphia chromosome-positive acute lymphoblastic leukemia following autologous bone marrow transplantation in first complete remission.
  • We describe the clinical outcome of autologous bone marrow transplantation (ABMT) for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL).
  • Between 1985 and 2000, 14 patients in first complete remission underwent transplantation.
  • In all cases, harvested marrow was purged with a cocktail of complement and monoclonal antibodies to common acute lymphoblastic leukemia antigen (CALLA).
  • For the 6 surviving patients in continuous remission, the median follow-up period was 96 months.
  • [MeSH-major] Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual. Recurrence. Remission Induction. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17321992.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Patel V, Macdonald JK, McDonald JW, Chande N: Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev; 2009;(4):CD006884
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate for maintenance of remission in Crohn's disease.
  • Although purine antimetabolites are moderately effective for maintenance of remission patients often relapse despite treatment with these agents.
  • OBJECTIVES: To conduct a systematic review of randomized trials examining the efficacy and safety of methotrexate for maintenance of remission in Crohn's disease.
  • SELECTION CRITERIA: Randomised controlled trials (RCTs) that compared methotrexate to placebo or any other active intervention for maintenance of remission in Crohn's disease were eligible for inclusion.
  • The main outcome measure was the proportion of patients maintaining clinical remission as defined by the studies and expressed as a percentage of the total number of patients randomized (intention to treat analysis).
  • A pooled analysis (n = 98) including one high quality trail (n = 76) showed that intramuscular methotrexate (15 mg/week) was significantly more effective than placebo for maintenance of remission in Crohn's disease (OR 3.11; 95% CI 1.31 to 7.41; P = 0.01).
  • A pooled analysis of two small studies (n = 50) showed no difference between methotrexate and 6-MP for maintenance of remission (OR 2.63; 95% CI 0.74 to 9.37; P = 0.14).
  • AUTHORS' CONCLUSIONS: Intramuscular methotrexate at a dose of 15 mg/week is safe and effective for maintenance of remission in Crohn's disease.
  • Oral methotrexate (12.5 to 15 mg/week) does not appear to be effective for maintenance of remission in Crohn's disease.
  • [MeSH-minor] Administration, Oral. Drug Administration Schedule. Humans. Injections, Intramuscular. Randomized Controlled Trials as Topic. Remission Induction

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2014;8:CD006884 [25157445.001]
  • (PMID = 19821390.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 21
  •  go-up   go-down


94. Degmecić D, Pozgain I, Filaković P, Dodig-Curković K, Mihanović M: Psychopharmacotherapy and remission of patients with schizophrenia. Coll Antropol; 2009 Jun;33(2):547-51
MedlinePlus Health Information. consumer health - Schizophrenia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychopharmacotherapy and remission of patients with schizophrenia.
  • Schizophrenia is a clinical syndrome of variable, but profoundly disruptive, psychopathology that involves cognition, emotion, perception and other aspects of behavior The Remission in Schizophrenia Working Group (RSWG) has defined criteria for symptomatic remission based on achieving and maintaining a consistently low symptom threshold for at least six consecutive months.
  • Aim of our study was to determine which antipsychotic are used in the treatment of patients with schizophrenia, as well as to assess are there differences between patients treated with typical and atypical antipsychotics and how many of them are in remission according to the defined remission criteria.
  • All of them were assessed with specially designed questionnaire about sociodemographic data, than with 8 item of PANSS (remission criteria), and with Clinical Global Impression scale.
  • Authors did not found statistically significant differences in two groups of patients regarding the scores on PANSS, CGI and number of patients in remission.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Psychopharmacology. Remission Induction. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19662777.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


95. Bhushan B, Ahuja D, Verma S, Saluja S, Siddiqui S, Kapur S: Relation of cell viability and apoptosis with clinical remission following induction chemotherapy in ALL and AML. J Exp Clin Cancer Res; 2007 Sep;26(3):313-21
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation of cell viability and apoptosis with clinical remission following induction chemotherapy in ALL and AML.
  • Evaluation of in vitro spontaneous apoptosis of acute leukemic blast cells after incubating for different time period and its correlation with clinical outcome is well documented in the literature.
  • Cell viability was evaluated in freshly isolated leukemic cells from 84 patients with acute leukemia (AL) using 7-Amino-Actinomycin D and was correlated with the clinical response following induction chemotherapy.
  • Patients with ALL who achieved complete remission (CR) had significantly lower mean live cell (70.9%) compared to those patients who did not achieve CR (93.3%) (p=0.02).
  • A lower cell viability and higher apoptosis in freshly isolated leukemic cells at the time of diagnosis may indicate a favorable response in patients with ALL but may not provide any sufficient information in predicting the response in AML patients to induction chemotherapy.
  • [MeSH-major] Apoptosis. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Cell Survival. Flow Cytometry. Humans. Remission Induction. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17987789.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


96. Benchimol EI, Seow CH, Otley AR, Steinhart AH: Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev; 2009;(1):CD002913
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Budesonide for maintenance of remission in Crohn's disease.
  • BACKGROUND: Corticosteroids have been shown to be effective for induction, but not maintenance of remission in Crohn's disease.
  • Budesonide has been shown to be effective for induction of remission in Crohn's disease.
  • OBJECTIVES: To evaluate the efficacy and safety of oral budesonide for maintenance of remission in Crohn's disease.
  • The study population included patients of any age with Crohn's disease in remission.
  • The primary outcome was maintenance of remission at various reported follow-up times during the study, up to 12 months following enrollment.
  • Budesonide 6 mg daily was no more effective than placebo for maintenance of remission at 3 months (RR 1.25; 95% CI 1.00 to 1.58; P = 0.05), 6 months (RR 1.15; 95% CI 0.95 to 1.39; P = 0.14), or 12 months (RR 1.13; 95% CI 0.94 to 1.35; P = 0.19).
  • Budesonide was not more effective than weaning doses of prednisolone for maintenance of remission at 12 months (RR 0.79; 95% CI 0.55 to 1.13; P = 0.20), but was better than mesalamine 3 grams per day (RR of remission 2.51; 95% CI 1.03 to 6.12; P = 0.04).
  • No differences in efficacy were detected based on the different formulations of budesonide, methods used to induce remission, or budesonide dose.
  • AUTHORS' CONCLUSIONS: Budesonide is not more effective than placebo or weaning prednisolone for maintenance of remission in Crohn's disease.
  • Therefore, budesonide is not recommended for maintenance of remission in Crohn's disease.
  • [MeSH-minor] Administration, Oral. Humans. Randomized Controlled Trials as Topic. Recurrence. Remission Induction. Risk

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2014;8:CD002913 [25141071.001]
  • [UpdateOf] Cochrane Database Syst Rev. 2001;(1):CD002913 [11279777.001]
  • (PMID = 19160212.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 51333-22-3 / Budesonide
  • [Number-of-references] 40
  •  go-up   go-down


97. Oakley A, Ng S: Grzybowski's generalized eruptive keratoacanthoma: remission with cyclophosphamide. Australas J Dermatol; 2005 May;46(2):118-23
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grzybowski's generalized eruptive keratoacanthoma: remission with cyclophosphamide.
  • However, cyclophosphamide 100 mg daily for 1 month followed by 3 months at 200 mg daily resulted in remarkable improvement and eventual remission without further treatment.
  • [MeSH-major] Keratoacanthoma / diagnosis. Mouth Diseases / diagnosis
  • [MeSH-minor] Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Female. Humans. Lip / pathology. Middle Aged. Mouth Mucosa / pathology. Remission Induction

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842409.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


98. Mahadevan U: TNF-alpha antagonists: benefits beyond remission. Rev Gastroenterol Disord; 2007;7 Suppl 1:S13-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNF-alpha antagonists: benefits beyond remission.
  • The anti-tumor necrosis factor-a (TNF-a) agents infliximab, adalimumab, and certolizumab pegol have proven efficacy for induction and maintenance of remission among patients with moderate to severe Crohn's disease.
  • [MeSH-minor] Antibodies, Monoclonal. Humans. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392633.001).
  • [ISSN] 1533-001X
  • [Journal-full-title] Reviews in gastroenterological disorders
  • [ISO-abbreviation] Rev Gastroenterol Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Tumor Necrosis Factors
  • [Number-of-references] 22
  •  go-up   go-down


99. Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, Craddock C, Liakopoulou E, Fielding AK, Mackinnon S, Olavarria E, Potter MN, Russell NH, Shaw BE, Cook G, Goldstone AH, Marks DI: Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica; 2009 Oct;94(10):1399-406
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission.
  • BACKGROUND: Approximately 40% of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia achieve long-term survival following unrelated donor hematopoietic stem cell transplantation in first complete remission but severe graft-versus-host disease remains a problem affecting survival.
  • Although T-cell depletion abrogates graft-versus-host disease, the impact on disease-free survival in acute lymphoblastic leukemia is not known.
  • DESIGN AND METHODS: We analyzed the outcome of 48 adults (median age 26 years) with high-risk, Philadelphia-chromosome-negative acute lymphoblastic leukemia undergoing T-cell depleted unrelated donor-hematopoietic stem cell transplantation (67% 10 of 10 loci matched) in first complete remission reported to the British Society of Blood and Marrow Transplantation Registry from 1993 to 2005.
  • The incidences of grades II-IV and III-IV acute graft-versus-host disease were 27% (95% CI 16-44) and 10% (95% CI 4-25), respectively.
  • High-risk cytogenetics at diagnosis was associated with a lower 5-year overall survival (47% (95% CI 27-71) vs. 68% (95% CI 44-84), p=0.045).
  • CONCLUSIONS: T-cell depleted hematopoietic stem cell transplantation from unrelated donors can result in good overall survival and low non-relapse mortality for adults with high-risk acute lymphoblastic leukemia in first complete remission and merits prospective evaluation.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Humanized. Female. Follow-Up Studies. Humans. Living Donors. Male. Middle Aged. Registries. Remission Induction. Risk Factors. Survival Rate / trends. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2000 Feb;25(4):411-7 [10723585.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Nov;14(11):1245-52 [18940679.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(1):69-76 [10918407.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] Cytotherapy. 2001;3(3):197-201 [12171726.001]
  • [Cites] Blood. 2003 Jul 1;102(1):404-6 [12623851.001]
  • [Cites] Ann Hematol. 2004 Apr;83(4):201-5 [14648023.001]
  • [Cites] Blood. 2004 May 15;103(10):3986-8 [14764530.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] Haematologica. 2004 Jul;89(7):809-17 [15257932.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Lancet. 1987 Jul 25;2(8552):175-8 [2885638.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Blood. 1991 Oct 15;78(8):2120-30 [1912589.001]
  • [Cites] N Engl J Med. 1993 Mar 4;328(9):593-602 [8429851.001]
  • [Cites] Transplantation. 1994 Oct 27;58(8):887-91 [7940731.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2580-7 [7989932.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):305-8 [8704678.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):931-6 [9508175.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3028-37 [15256423.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3308-13 [16046530.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(2):155-63 [16284608.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2657-63 [16703597.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Blood. 2008 Jul 15;112(2):426-34 [18398065.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3996-4003 [10845940.001]
  • (PMID = 19648167.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  • [Other-IDs] NLM/ PMC2754956
  •  go-up   go-down


100. Chim CS, Lie AK, Liang R, Au WY, Kwong YL: Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor. Bone Marrow Transplant; 2007 Aug;40(4):339-47
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor.
  • We analyzed the outcome of 108 adult acute lymphoblastic leukemia patients undergoing allogeneic bone marrow transplantation (BMT).
  • Philadelphia (Ph) chromosome occurred in 35.2% patients at diagnosis.
  • Two-thirds of patients received allogeneic BMT in first complete remission (CR1) BMT.
  • Salvage BMT was performed in 21 and 16 patients at second complete remission (CR2) and beyond CR2.
  • Multivariate analyses (including age, sex, disease status, donor type, acute graft-versus-host disease (aGVHD), stem cell source, cytogenetics, grade 1/2 aGVHD and TBI-containing conditioning regimen) identified age<35, BMT at CR1 and grade 1/2 aGVHD as favorable factors for OS.
  • [MeSH-major] Bone Marrow Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Disease-Free Survival. Female. Graft vs Host Disease. Histocompatibility Testing. Hong Kong. Humans. Kaplan-Meier Estimate. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Salvage Therapy. Transplantation, Homologous






Advertisement